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SUMMARY 
 
Objective: MicroRNAs (miRNAs) are small 20- to 24-nt non-coding RNAs 
involved in the post-transcriptional regulation of gene expression which play 
important defensive roles in several viral infections. Global expression 
profiles of cellular miRNAs have identified alterations in the expression of 
specific miRNA post-HIV-1 infection both in vitro and in different patient 
cohorts, suggesting a potential role for miRNAs in the pathogenesis and 
progression of HIV-1 infection. We therefore decided to verify if natural 
resistance to HIV-1 infection, observed in seronegative individuals 
repeatedly exposed to HIV-1 (HESN) through unprotected sexual 
intercourse, could be secondary to a different expression of their miRNA 
profile. 
 
Methods: Expression level of 84 miRNAs was analyzed by RT-PCR array in 
plasma and unstimulated PBMC of 30 seronegative individuals repeatedly 
exposed to HIV (HESN), 30 HIV seropositive subjects (HIV+) and 30 healthy 
controls (HC). Results were confirmed by individual RT-qPCR in plasma, in 
vitro HIV infected PBMC and supernatants, isolated monocyte and in in vitro 
HIV infected monocyte derived macrophages (MDM). ABCA1, Dicer and 
Drosha mRNA expression was analyzed as well. 
 
Results: Whereas Dicer and Drosha expression was comparable in HESN, 
HIV+ and HC, several miRNA were upregulated both in HESN and HIV+ 
compared to HC, suggesting that exposure to HIV modifies miRNA signature 
even in the absence of productive infection. MiRNA-29a and miR-223 were 
upregulated in both unstimulated PBMC and plasma of HESN alone; their 
expression was reduced upon in vitro HIV infection of HESN PBMC 
indicating that, upon infection, they are secreted in the extracellular milieu. 
These results were confirmed by individual qPCR. 
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Additionally, HESN miRNA profile in monocytes clustered with HC one, 
while, reduced susceptibility to HIV-1 infection in in vitro HIV infected MDM 
from HESN was associated with higher expression of all our tested miRNAs 
compared to HCs. Finally, the upregulation of miR-223 in basal PBMC, 
monocytes and HIV-1 infected MDM resulted into an increased expression of 
ABCA1. 
 
Conclusions: Our studies demonstrate that HIV exposure modifies miRNAs 
expression. Because those miRNAs that are specifically increased only in 
HESN have been known to reduce HIV replication via the binding of viral 
mRNA 3’ UTRs, the modulation of these miRNAs could represent an 
important mechanism in resistance to HIV. 
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1.1. Origin and History of HIV 
The cross-species transmission of simian immunodeficiency viruses from 
chimpanzees to humans in West–Central Africa was the emergence of HIV-1 
at the beginning of the 20th century (Worobey M. 2008).  
With having infected far more than 60 million people, HIV-1 has been one of 
the most successful pathogens in human history (Osseo-Asare AD, 2007). In 
1970s, the virus was only detected in east Africa (Bello G, 2008) and by 
1980, in Europe and North America, although the actual introduction 
probably occurred decades earlier (Worobey M. 2008). In 1983 for the first 
time, the viral etiology was identified in a new retrovirus particle by Fracoise 
Barré-Sinoussi and Luc Montagne (for which they won the Noble Prize in 
2008), later in 1984 the team of Robert C. Gallo confirmed to be the 
etiological agent of acquired immunodeficiency syndrome (AIDS) (Vicenzi at 
al., 2013). 
The universal spread of HIV-1 during the latter half of the 20th century is 
generally attributed to expanded migration between countries as a result of 
globalization; increasing urbanization; warfare and ethnic conflict 
surrounding postcolonization independence of many African countries; and 
changing sexual practices (Vidal N, 2000). The cumulative total of individuals 
infected with HIV-1 and deaths due to AIDS since the pandemic began 
exceeds 60 million and 25 million people respectively (Cohen MS, 2008). At 
the end of 2007, the Joint United Nations Program on HIV/AIDS (UNAIDS) 
and the WHO (World Health Organization) estimated that there were 33.2 
million people living with HIV-1, that 2.5 million individuals became newly 
infected in 2007 and in fact 2.1 million people died of AIDS in that year 
(Cohen MS, 2008).  
Also, the state of profound immunodeficiency caused by HIV infection leads 
to the co-infection by other opportunistic pathogens, like Mycobacterium 
tuberculosis, hepatitis viruses and degeneration of central nervous system 
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as well as the development of tumors mostly Kaposi’s sarcoma and B-cell 
lymphoma (Vicenzi at al., 2013). 
1.2. HIV Virology 
1.2.1. HIV Classification 
HIV virus belongs to the viral Retroviridae family and the genus Lentivirus. 
There are two different types of HIV, which can cause infection and disease 
in humans, HIV-1 and HIV-2. HIV-1 arised from cross-species transmission 
of a chimpanzee virus to humans (Hahn B.H., 2000) and HIV-2 from cross-
species transmission of a Sooty mangabey virus (Lemey P., 2003).  
There are three groups of HIV-1, labeled M, N, and O, based on genome 
differences. Most HIV-1 infections are caused by group M viruses, and these 
are divided into 9 subtypes known as clades (A–D, F–H, J, and K). The DNA 
sequences of viruses in distinct clades can differ by 15%–20% (McCutchan 
F.E. 2000). The most common clade in the Americas, Europe, and Australia 
is clade B, whereas clade C predominates in the most heavily affected part 
of the world, southern Africa (McCutchan F.E. 2000).  
In comparison with HIV-1, HIV-2 is much less prevalent, and individuals 
infected with HIV-2 are primarily found in West Africa and India. In addition, 
infection with HIV-2 is associated with a slower progression to immune 
deficiency, and the virus seems to be less efficiently transmitted, even from 
infected women to their offspring (Jaffar S., 2004). 
 
1.2.2. HIV structure 
An infectious HIV particle consist of a phospholipid bilayer envelope derived 
from the host cell membrane but containing virally encoded membrane 
proteins, which surround two identical single strands of RNA (ssRNA) 
packaged within a core of viral proteins (Fig. 1.1) (Abbas AK, 2010). 
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Figure1.1. Structure of HIV-1 virus (Abbas AK, 2010). 
 
The HIV genome is 9.2kb long approximately and has the basic 
characteristic of retroviruses. At each end of the genome, there are long 
terminal repeats (LTR), which regulate viral gene expression and 
integration. Also, It encodes the envelope (Env) glycoproteins consisting of 
surface gp120 and transmembrane glycoprotein gp41 (Zhu, P. et al, 2006) 
which are required for HIV infectivity. The Gag sequences encode a 55-kD 
protein that is cleaved into the internal structure core proteins (p24, p9, p7 
and p17). The Pol sequences encode the enzymatic polymerase proteins 
including, reverse transcriptase (RT), integrase (IN) and protease (PR) 
required for viral replication. In addition to these classic retrovirus genes, 
there are six other accessory proteins, namely, Vif, Vpr, Rev, Vpu, Tat and 
Nef (Turner et al., 1999). 
Vif, virion infectivity factor, is considered as a prototype of viral antagonist of 
host-cell factors which can restrict or prevent virus infection or replication 
and it is essential for the production of highly infectious mature virions 
(Cohen EA, 1996). 
Vpr, viral protein R, is a part of pre- integration complex (PIC) that mediate 
the transport of viral genome to the nucleus while undergoing conversion 
from RNA into DNA as result of the virion– associated reverse transcriptase 
enzyme.  It includes a nuclear localization signal (NLS) that directs transport 
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even in the absence of mitotic nuclear envelope breakdown and it is 
essential for nuclear localization in non-dividing cells, such as macrophages 
(Gallay P, 1996). In addition at cellular level, Vpr induces cell cycle arrest in 
the G2/M phase but also apoptosis (Subbramanian et al., 1998). 
Newly synthesized Env glycoproteins (gp160), which are later cleaved into 
gp120 and gp41, are sometimes held in the endoplasmic reticulum (ER) 
through interactions with newly synthesized CD4 molecules. The other 
important protein, viral protein unique (Vpu), promotes degradation of CD4 in 
these complexes, thus allowing Env transport to the cell surface for 
assembly into viral particles (Lamb RA, Pinto LH, 1997). Vpu is only present 
in HIV-1 and by preventing Bone marrow stromal cell antigen 2 (BST-2) or 
Tetherin, a host cell protein, plays an important role in budding and release 
of new virions in the final step of the virus life cycle (Andrew A, et al., 2010). 
 
1.2.3. HIV life cycle 
The Env complex has a trimeric structure of three gp120/gp41 pairs. An 
initial binding between gp120 subunits to the surface receptor CD4 molecule 
induces the conformational changes that expose secondary gp120 binding 
site for a second cell surface molecule, typically CC-chemokine receptor 5 
(CCR5) (Rizzuto, C. D. 1998).  
The HIV core includes integrase (IN), replication enzymes RT and the viral 
genomic RNA and it is encased by viral capsid (CA) protein (Briggs, J. 
A. 2006). Once an HIV virion enters a cell, the CA becomes disrupted and 
the RNA genome of HIV is transcribed into a double strand DNA by reverse 
transcriptase (Kohlstaedt, L. A. 1992). The integration of viral DNA is 
catalyzed by viral IN into the host genome. The integrated HIV DNA  called 
provirus, with little or no production may remain transcriptionally inactive for 
months or years and in this way HIV infection can be latent (Abbas AK, 
2010).  
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The transcription of the genes is regulated by LTRs upstream of the viral 
structural genes. The LTRs contain polyadenylation signal sequences, the 
TATA box promoter sequence and binding sites for two host cell 
transcription factors, NF-ĸB and SP1 (Liu R et al., 1996). Activation of the T 
cells by antigen or cytokines is linked to initiation of HIV gene transcription. 
The first gene products of transcription are Nef, Tat and Rev proteins that 
are exported and translated into proteins in the cytoplasm and later, the 
structural components of the virus include pol, gag, and env are translated 
(Daugherty, M. D.,2010).  
HIV-1 negative factor, Nef is expressed shortly after viral infection in high 
concentrations, and it increases viral replication and stimulates a decline in 
the number of CD4 receptors on the surface of the infected cells (Goldsmith, 
et al., 1995). Tat is a transcriptional activator and can enhance the 
production of viral mRNA transcript. It binds to nascent mRNA transcript and 
recruits cyclin T, the cellular protein, to enhance its affinity and increase the 
“processivity” of RNA polymerase by several hundred-fold (Wei et al, 1998). 
The major function of Rev is controlling the export rate of mRNA in order to 
regulate the expression of HIV proteins (M.Emerman and Malim, 1998).  
Subsequently, the pol gene is cleaved to form reverse transcriptase, 
protease, ribonuclease, and integrase enzymes. The viral protease cleaves 
the gag protein proteolitically into p24, p17 and p15 polypeptides, which are 
the core proteins required for assembly of infectious viral particles (Turner et 
al., 1999). The gp120 and gp41 proteins, necessary for HIV binding to cells, 
are the product of env genes from cleaving of gp160 by cellular proteases 
(Wyatt and Sodroski, 1998). 
The viral particle assembles by packaging viral RNA transcripts within a 
nucleoprotein complex which consist of the pol-encoded enzymes and gag 
proteins required for next integration. Later the assembled complex is 
enclosed within an envelope and released by budding from the plasma 
membrane of the infected cells (Greene et al., 2002). (Fig.1.2) 
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Figure 1.2 HIV life cycle. Viral fusion and entry requires the binding of glycoprotein gp120 to 
CD4 receptors at the cell surface as well as to CC chemokine receptor type 5 (CCR5) or CXC 
chemokine receptor type 4 (CXCR4). The viral nucleocapsid enters the cytoplasm and uses 
cytoplasmic dynein to move toward the nuclear pore complex (NPC). The viral RNA is 
retrotranscribed into proviral double-stranded cDNA (dscDNA), which can stay in the cytosol, 
where it is highly unstable and exists in a transient, reversible pre-integration latent state, or 
can form a pre-integration complex consisting of dscDNA, viral proteins and some host cell 
proteins. When ATP levels are adequate, the pre-integration complex is transported into the 
nucleus through the NPC, and the dscDNA either circularizes as one or two long terminal 
repeat-containing circles or is integrated into a host cell chromosome. After integration, the 
provirus remains quiescent, existing in a permanent post-integration latent state. On 
activation, the viral genome is transcribed by the synergic interaction of cellular transcription 
factors (nuclear factor-κB (NF-κB), nuclear factor of activated T cells (NFAT) and specificity 
protein 1 (SP1)) and the viral transactivator, Tat. Rev, a viral protein, regulates the splicing 
and cytosolic transport of some of the viral mRNAs, which are translated into regulatory and 
structural viral proteins. New virions assemble and bud through the cell membrane, maturing 
through the activity of the viral protease (Card et al, Retrovirology 2013). 
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1.3. HIV pathogenesis 
1.3.1. HIV Transmission  
Each HIV transmission event results from exposure to blood, a blood 
product, or bodily secretions contaminated with HIV virus. This may occur 
through sexual transmission (heterosexual or homosexual), parenteral 
transmission (injection drug use, receiving contaminated blood products), 
or vertical transmission (transmission of HIV from mother to child in utero or 
trough breast-feeding) (Simon V et al., 2006). The probability of a 
transmission event, whether from blood, sexual intercourse, or vertical 
transmission, broadly correlates with the concentration of HIV-1 in the host 
secretion (Quinn TC, 2000).  
 
1.3.2. Disease progression 
A majority of HIV infected individuals have acute HIV symptoms 
approximately, 2-4 weeks after transmission of the virus (Figure 1.3), 
characterized by flu-like clinical appearances combined with plasma viremia 
and frequently fever and lymphadenopathy (Gurunathan S, 1997). Other 
reported symptoms are myalgias, skin rash, headache, anorexia, and 
diarrhea (Gurunathan S, 1997), although the severity of these clinical 
symptoms may vary greatly between individuals.   
During the early phase, plasma viremia peaks as high as 10 million viral 
copies per milliliter and the virus replicates aggressively in the absence of an 
immune response (Piatak M Jr, 1993). This step is followed by a sharp drop 
in viral load as a consequence of HIV- specific CD8+ T cells appearance 
(Helz et al., 2006) and it is known as viral set point. The rate of disease 
progression in HIV- infected patients is determined by the level of the viral 
set point, as individuals with low viral set point tend to display slower 
progression to AIDS (Mellors et al, 1996). 
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The acute phase of infection is accompanied by a sharp decline in the CD4+ 
T cell levels in the peripheral blood, which may rebound as viral replication 
is contained. This depletion of CD4+ T cells may be associated with the 
wide depletion of CCR5+ memory CD4+ T cells in the gut-associated 
lymphoid tissue (GALT) leading to prompt dysregulation of gut immunity 
(Mattapallil et al, 2005).  
Acute infection is followed by a much longer chronic phase, in which 
turnover of CD4+ T cells is enormous and there is a gradual drop of CD4+ T 
cells in the periphery. The onset of AIDS appears when the CD4+ T cell 
count declines below 200 cells/µl of blood (Stevenson et al., 2003). At this 
point, the immune system is unable to cope with infectious challenges, and 
the host ultimately surrenders to opportunistic infections.   
     
 
Figure 1.3. Clinical and immunologic events associated with disease progression in untreated 
HIV-1 infection 
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1.4. HIV immunology 
1.4.1. Innate response to HIV infection 
The innate immune system is the first line of defense against pathogens and 
consists of epithelial barriers, complement system, cells with phagocytotic 
and antigen presenting properties, such as granulocytes, macrophages, and 
dendritic cells (DCs) (Mogensen TH, 2009). Innate immune cells are capable 
to recognize the infection by pattern recognition receptors (PRRs) due to 
their ability to identify evolutionarily conserved structures on pathogens, 
termed pathogen-associated molecular patterns (PAMPs). 
Among PRRs, the family of Toll-like receptors (TLRs), with 10 different sub 
families has been identified. TLR1, 2, 4, 5, 6, and 10 are expressed at the 
cell surface and generally recognize hydrophobic molecules unique to 
microbes and not produced by the host. In the other hand, TLR3, 7, 8, and 9 
are located almost only in endosomal compartments and are particular in 
recognition of nucleic acids (Medzhitov R, 2000). So in viral infections, the 
recognition is mediated by TLR9 recognizing DNA, as well as by TLRs 7, 8 
and 3 detecting single-stranded RNA (ssRNA) and double-stranded RNA 
(dsRNA) respectively (Lund J, 2003). 
Stimulation of TLR7, 8 induces the production of several antiviral and 
immunomodulatory cytokines. Recently, the cascade of cytokine production 
in the periphery has been thoroughly documented, showing an initial rapid 
increase in the level of interferon α (IFNα) followed by Interleukin- 15 (IL-15) 
and CXC-chemokine ligand 10 (CXCL10) which rise promptly but transiently. 
The other important cytokines like, IL-18, tumor necrosis factor α (TNFα), 
IFNγ and IL-22 also increase promptly and are sustained at high levels, 
whereas the increase in IL-10 is slightly delayed (Stacey, A. R. et al, 2009). 
The cellular sources of these cytokines include DCs, infected CD4+CCR5+ T 
cells, monocytes, macrophages and natural killer (NK) cells which are 
fundamental in shaping the immune responses that develop in acute or early 
HIV-1 infection (Cameron, M. J. et al. 2007). 
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IFNα acts to inhibit HIV replication at multiple stages in the viral lifecycle by 
different mechanisms including blocking the early steps of HIV replication, 
inhibition of HIV gene expression, and effects on viral assembly and budding 
(Beignon et al., 2005; Lee et al., 2006).  
IFNα inhibits the replication of HIV through mechanisms mediated by the so 
called Interferon stimulated genes (ISG) such as ABOPEC3G, Mx2, OAS, 
IL8, IFNg ect. These effector molecules undermine viral replication at 
different levels inhibiting HIV gene expression, affecting viral nuclear import, 
assembly and budding. HIV-1 triggers the secretion of IFNα by activation of 
plasmacytoid dendritic cells (pDCs) via TLRs in acute HIV-infection (Beignon 
et al., 2005; Lee et al., 2006). Apolipoprotein B mRNA editing enzyme-
catalytic polypeptide-like 3G (APOBEC3G), acts to restrict HIV replication in 
newly infected cells by editing C -> U in HIV DNA negative strand, 
introducing premature stop codons and inhibiting reverse transcription and 
chromosomal integration (Casartelli et al., 2010). HIV counters this form of 
host defence through virion infectivity factor (Vif), which targets APOBEC3G 
for proteasomal degradation. Howeve, it has been shown that IFNα is able to 
induce APOBEC3G expression by macrophages to overcome and abolish 
HIV Vif neutralization of APOBEC3G proteins and consequently decreases 
HIV replication markedly (Peng et al., 2006).   
Acute HIV-1 infection is also characterized by the activation and expansion 
of NK cells which might be the result of high levels of proinflammatory 
cytokines such as IL-15 and IFNα secreted by DCs and monocytes. In 
particular, a significant increase of NK cells before the development of any 
detectable antibody responses has been detected in acute HIV-1 infection 
(Alter et al., 2007). However, along with viral replication and disease 
progression, the initial expansion of NK cells becomes gradually defective.  
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1.4.2. HIV-specific B cells and antibodies 
B cells producing antibody mediate the humoral immune response. Virus 
specific antibodies play an essential role in the viral infection by preventing 
infections of the host cells (Burton DR, 2002). The humoral immune 
response is activated following uptake and digestion of viral proteins by DCs 
into small peptides. DCs present the digested antigen on major 
histocompatibility complex (MHC) II molecules to CD4+ T helper cells (Th) 
which produce B cells stimulating cytokines including IL-4, IL-5, IL-6, IL-10, 
and transforming growth factor β (TGF−β) to activate naïve B cells. Latter, B 
cells recognize specific epitopes or intact virus through their surface IgM and 
differentiate into plasma cells to produce large amounts of IgG, IgA, IgE 
antibodies and memory B cells. During HIV-1 infection antibodies against 
gp120, gp41, the nucleocapsid (p24) and the matrix (p17) arise few weeks to 
several months after infection. This process is commonly referred to as 
seroconversion (Wei X et al. 2003).  
The virus neutralization is characterized by the interaction of specific 
antibodies with the viral envelope spikes. This interferes with virus 
attachment or viral entry in target cells and results in the inhibition of 
infection. Only a minority of anti-HIV Env antibodies, at any time, exerts 
immune pressure by autologous neutralization. However, the virus easily 
mutates and readily escapes from these potentially protective immune 
responses (Wei X et al. 2003). During the chronic course of infection only 
20% of the infected individuals generate broadly neutralizing antibodies 
(bNAbs) capable to neutralize heterologous viruses (Stamatatos L. et, al. 
2009). In addition to classical neutralization, antibodies can attach to HIV 
infected cells and kill them via antibody dependent cellular cytotoxicity 
(ADCC) mediated through their Fc moiety and NK (Aasa-Chapman MMI, 
2005) (Hessell AJ, 2007).    
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1.4.3. HIV-specific T cells 
Another important arm of adaptive immune system is the cellular immune 
response which consists of T lymphocytes which can be divided into two 
main clusters: T helper (Th) CD4 T cells and Cytotoxic CD8 T cells (CTL).  
Following their activation by antigens and co-stimulatory signals, CD4+ Th 
cells can differentiate into various distinct subsets of effector Th cells such 
as Th1, Th2 and Th17,  
Th1 cells usually produce Type 1 cytokines such as IFNγ, TNFa and IL-2 
required for the clearance of intracellular pathogens; whereas Th2 cells 
produce IL-4, IL-5 and IL-13, which activate humoral immune response 
against extracellular pathogens (Wilson, C. B., Rowell, E. & Sekimata, 
M. 2009).  
CTL exert a cytotoxic activity and can detect and eliminate infected cells in 
different ways. MHC I molecules present the intracellular antigens on the 
surface of infected cells which can be recognized by precursor cytotoxic 
CD8+ T lymphocytes. Also, antigen presenting cells (APCs) can induce CD4+ 
T cells to produce IL-2, IFN-γ, and TNF-α which activate and differentiate the 
CTLs into memory or effector CTLs. Later, by producing perforines and 
granzymes, effector CTLs can directly kill infected cells (McMichael AJ, 
2001).  Additionally, after interaction of Fas ligand on CTLs with Fas receptor 
on infected cells, CTLs can promote apoptosis of the infected cells (Gehri R, 
1996). Moreover, CTLs can exhibit a non-cytotoxic antiviral function by 
producing several cytokines, chemokines and CD8+ T cell antiviral factors 
(CAF) (Saksena NK, 2008) (Figure 1.4). 
HIV-specific CD8+ T cells appear within the first few weeks of infection as 
peak viremia drops, and correlate with the development of viral escape 
mutant, suggesting a key role for CD8+ T cells in controlling viral replication. 
Supporting this hypothesis , viral replication in vitro can be inhibited by 
isolated CD8+ T cells from HIV-infected individuals (Saez-Ciriòn et al., 2007), 
and deficiency in CD8+ T cells response in Simian immunodeficiency viruses 
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(SIV)-infected macaques results in a loss of viral control and rapid disease 
progression (Jin X et al., 1999) (Figure 1.4). 
 
Figure 1.4. HIV-induced T cell responses. HIV specific CD8+ effector cells produce 
chemokines and cytokines in order to eliminate infected cells. CD4+ T helper cells help to 
stimulate both dendritic cells and CD8+ T-cells to maintain a CD8+ T-cell memory response. 
HIV interferes with this supportive function of CD4+ T-cells. (Winni De Haes et al. 2012). 
 
The earliest CD8+ T cell are generally Env- and Nef-specific while responses 
to other viral proteins, including Gag and Pol usually appear with viral control 
later in infection (Turnbull, E. L. et al, 2009). HIV infects and depletes CD4+ 
T cells and HIV- specific memory cells, however strong HIV- specific CD4+ T 
cell responses can be rescued by early administration of Anti-Retroviral 
Therapy (ART) (Rychert et al., 2007). 
HIV-1 can escape from the host CD8+ T cell recognition because of ongoing 
viral recombination and mutations. The continuous mutation in HIV-1 is the 
major obstacle to vaccine design and determines the big viral variety in a 
single HIV-1-infected individual as well as the significant sequence variation 
in circulating viral strains at the population level.  However, it has been 
proposed that the capability of HIV-1 to escape immune response is limited 
and has some cost for the virus (Goepfert PA et al. 2008).  
Exposure of HIV-specific T cells to persistent viremia leads to functional 
exhaustion during chronic infection. T cell exhaustion is a state of T cell 
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dysfunction defined by loss of proliferation capacity besides polyfunction and 
cytotoxic ability, followed by apoptosis (Wherry EJ, 2004). Up-regulation of 
different inhibitory molecules on the cell surface is the main feature of 
functional exhaustion, including programmed death 1 (PD-1), Cytotoxic T-
Lymphocyte Antigen (CTLA)-4, lymphocyte activation gene (LAG)-3, T cell 
immunoglobulin domain and mucin domain (Tim)-3, 2B4 (CD244) and 
CD160 (Wherry 2011). PD-1 has been identified as a critical negative 
regulator in HIV infection (Zhang et al., 2007), and Tim-3 has been linked to 
elevated sensitivity to Treg-mediated suppression (Elahi et al., 2011). 
1.5. Models of Natural Protection 
1.5.1. HIV-exposed seronegative individuals (HESN) 
Frequent and multiple exposures to the HIV do not necessarily result in HIV 
infection (Figure 1.5). Approximately 15% of HIV exposed seronegative 
individuals repeatedly resist infection, a phenomenon that has been 
observed in all investigated HIV-exposed cohorts. Despite this awareness, 
during the first years after AIDS discovery, little consideration was paid to the 
observation that mucosal exposure to HIV-1 would not consistently lead to 
infection, and none to the possibility that such putative noninfectious 
exposures might be secondary to inheritable factors (Shearer G, Clerici M, 
2010). 
Initial AIDS epidemiologic studies from the UCLA Multicenter AIDS Cohort 
Study (MACS) (Inagawa DT, 1989) demonstrated that, frequent unprotected 
sexual contacts in a limited percentage of homosexual men, did not 
automatically result in HIV sereoconversion.  
Moreover, presence of a differential susceptibility to HIV infection was 
reported in a subset of repeatedly exposed female sex workers in Kenya 
(Plummer F, 19993) (Fowke KR, 1996). Interestingly, HIV-specific T-helper 
cell responses were shown to be present in these repeatedly exposed 
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seronegative individuals, suggesting immunologic and/or genetic protection 
(Clerici M et al. 1992).  
Resistance to HIV infection has been subsequently described in intravenous 
drug users, healthcare workers accidentally exposed to HIV, homosexuals or 
heterosexual subjects that have unprotected sex with their seropositive 
partners and hemophiliacs who had received HIV-contaminated anticlotting 
factors (Miyazawa M, 2009). A particularly interesting cohort is represented 
by uninfected newborns of HIV-infected mothers. These infants are exclusive 
in that most of them are uninfected at birth (65–75%), despite having been 
continuously exposed to a HIV saturated environment during pregnancy; and 
are HIV seropositive, due to passively transferred maternal anti-HIV 
antibodies.  
At the beginning HIV-exposed uninfected individuals were referred to as 
exposed seronegatives (ESNs), exposed uninfected or multiple exposed 
uninfected (MEU). Since the early 1990s, numerous research groups have 
studied such cohorts of ESN to define immunological and/or genetic 
correlates of protection to HIV infection, but none of the identified 
mechanisms have so far been able to completely explain this phenomenon. 
Furthermore, efforts to compare results collected in different cohorts of ESN 
and in diverse laboratories have been problematic for many reasons, 
including the lack of clear definition of who should be classified as ESN 
(Biasin M, 2013). 
The first International Symposium on Natural Immunity to HIV held in 
Winnipeg, Canada was organized by the main investigators who had 
contributed to define the ESN/exposed uninfected phenotype in November 
2009. The most important purpose was to definitely lay out the inclusion 
criteria of the ESN individuals and to compare the results of studies 
performed on different ESN cohorts. Later it was followed by a second 
meeting in June 2010 in Rockville, MD during which the decision was made 
to refer to these individuals as HIV-exposed seronegative individuals (HESN) 
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(Young JM et al, 2011). More recently, (October 2014) a new meeting held in 
Cape Town, South Africa enlightened that while several HESN cohorts have 
been identified worldwide and are currently being studied by different 
groups, key information is still lacking. For instance, the relative contribution 
of genetic and immune factors to determine the phenomenon of resistance 
to HIV is not yet clarified. Notably, the possibility to study the early dynamic 
of this phenomenon is inhibited by the definition of the resistance phenotype 
itself. In fact, the HESN status is assigned only after an individual has been 
able to efficaciously resist infection – typically over a period of years – 
despite multiple, frequent and repeated documented exposures to the virus. 
Thus, researchers can only observe and compare the consequences of 
potentially important immunological changes that probably occurred years 
before the HESN status could be defined (Biasin M, 2013). Even so, if a 
genetic profile is at least partially responsible for this phenomenon it should 
be possible to identify this/these factor(s) at any time after exposure. 
Furthermore, once a putative protective variant gene is associated to the 
resistant phenotype, analysis can be easily performed using ex vivo infection 
assays on cells isolated from healthy controls carrying that specific mutation; 
it is therefore worthwhile to focusing energy in this research field. 
 
1.5.2 Genetic correlates of protection 
There is a considerable component of heredity in susceptibility to HIV-1 
infection. The first convincing evidence of this assumption dates back to 
1996 when it was discovered that individuals homozygous for the allelic32 
variant of the chemokine receptor CCR5, the main coreceptor for R5-HIV-1 
viruses, show a strong, although not absolute, protection to sexually 
transmitted HIV-1 infection (Piacentini, L. 2009) (Poropatich K & Sullivan DJ 
Jr. 2011). Based on this observation new anti-HIV drugs that block virus 
entry have been developed, and in 2009 a patient apparently recovered 
fromHIV-1 infection following transplantation of CCR5 32/32 stem cells 
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(Walker BD, 2007), thus pointing out the possibility of translating genetic 
research on HIV into effective therapies. 
More recently, Draenert showed that, whereas monozygotic twins infected 
with the same viral strain are characterized by a similar rate of progression, 
time to AIDS differs if infection with the same strain occurs in fraternal twins 
(Clerici M, 1992). These observations encouraged the search for host 
mutant restriction factors that could influence susceptibility and resistance to 
HIV-1. As a consequence, the scientific community is investing substantial 
resources to genetically characterize individuals with non-classical 
responses to HIV disease. The two main criteria adopted to identify genetic 
variants responsible for HIV-infection include: candidate gene approach and 
genome wide studies (GWAs). 
1.5.2.1. Candidate gene for protection 
Candidate gene studies indicate a first knowledge of the gene function in 
HIV-1 pathogenesis (Shea et al., 2012) and consider only variants in those 
genes known to be directly implicated in the HIV-1 life cycle or in the immune 
response to the virus, thus excluding still unidentified genetic factors 
potentially able to interfere with HIV-infection. So far, the most AIDS 
restriction genes have been identified within the human leukocyte antigen 
(HLA) class I locus (An et al., 2010) (Figure 1.5). For instance, the protective 
effect of HLAB57 has been correlated with the ability of HLAB57-restricted 
CTLs to target multiple HIV peptides. Indeed, the expression of HLAB*27 
has been illustrated to utilize a protective effect by preserving a high 
steadiness between the HLA B pocket and the arginine in position 2 of the 
gag peptide. In fact, mutations in this position lead to both instability of the 
B27-gag complex and faster progression to AIDS (Kelleher et al., 2007).  
Recently, the association between HESN phenotype and the endoplasmic 
reticulum aminopeptidases 2 (ERAP2), another gene involved in the antigen 
presentation pathway, has been found (Cagliani et al., 2010). ERAP2 has 
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been target of long-standing balancing selection (Andrés AM, et al, 2010) 
(Cagliani R et al, 2010). In particular, this process has maintained two highly 
differentiated ERAP2 haplotypes at intermediate frequency in most human 
populations (Andres AM et al, 2010) (Cagliani R et al, 2010). The two 
haplotypes, referred to as HapA and HapB, differ at multiple variants in tight 
linkage disequilibrium. HapB harbours the T allele for rs2549782 
(Asn392Lys) and the G allele for rs2248374; this latter has been shown to 
determine the activation of a cryptic splice site in intron 10 and the 
production of an alternatively spliced ERAP2 mRNA (ERAP2-AS) with an in-
frame stop codon (Cagliani R et al, 2010) (Coulombe-Huntington J, 2009). 
Thus, the predicted protein product of HapB-derived transcripts is a 
truncated protein of 534 amino acids, whereas the canonical ERAP2 protein, 
consisting of 960 amino acids, is encoded by a full-length mRNA (ERAP2-
FL) transcribed from HapA.  
The G allele of rs2549782, which tags HapA, was found to be significantly 
over-represented in HESN, indicating that association between rs2549782 
and HIV-1 protection follows a recessive model (Andres AM et al, 2010). 
Furthermore, genotype analysis in 104 HESN exposed to HIV through 
injection drug use (IDU-HESN) and 130 controls from Spain indicated that 
hapA protects from HIV infection. Meta-analysis with an Italian cohort of 
sexually-exposed HESN yielded a p value of 7.6 x10-5. HLAB typing 
indicated that the HLA-B*57 allele is significantly more common than 
expected among HESN homozygous for haplotype A (homoA). Data 
obtained in a cohort of 139 healthy Italian controls showed that following in 
vitro HIV-1 infection the expression of ERAP2-FL and a number of genes 
involved in antigen presentation as well as of MHC class I on the surface of 
CD45+ cells was significantly increased in homoA cells; notably, homoA 
PBMC, but not isolated CD4+ cells, were less susceptible to HIV-1 infection 
(Biasin M et al, 2013). The data collected so far seem to validate the 
hypothesis that this variant is able to generate a peptide repertoire 
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qualitatively and/or quantitatively different, which in turn is able to confer 
natural resistance to infection. 
Genetic studies also have established the association between NK activation 
and resistance to HIV infection. A higher frequency of inhibitory killer cell 
immunoglobulin–like receptor (KIR) genes in the absence of their associated 
HLA genes has been found in African HESN sex workers (Jennes et al. 
2006). Some studies showed that NK activation exerts a defensive effect in 
HIV infection which derives also from studies on the activating receptor allele 
KIR3DS1. Indeed, an increase of homozygosis for this receptor in HESN 
compared to HIV-infected patients has been found (Guerini et al., 2011), 
while there is a strong protection in the presence of this allele in parallel with 
its presumed HLAB ligand(s) (Carrington et al., 2008). 
Furthermore, HESN phenotype is associated with another molecular family 
including chemokines and chemokine receptors. Analysis of the relationship 
between CCL3L1 copy number and susceptibility to HIV-1 infection 
illustrated that CCL3L1 levels are inversely corresponded with CCR5 
expression on CD4+ T lymphocytes (Gonzalez et al., 2005). Additionally, the 
increase median copy number of CCL3L1 and the CCL3L1/CCL3 mRNA 
ratios has been detected in Human T-lymphotropic virus (HTLV)-2-infected 
individuals in HESN and Long Term Non Progressor (LTNP) compared to 
those seen in HIV-unexposed healthy controls (Pilotti E. et al, 2007). 
The other protective factor toward HIV-1 infection is new genotypes at 
chromosome 22q12-13 (Kanari Y, 2005) and it has been shown that the 
APOBEC3 locus is present in the middle of this chromosome. The 
APOBEC3 locus includes 7 members (A, B, C, DE, F, G and H) which 
display different rate of anti-HIV activity. Apolipoprotein B mRNA-editing 
enzyme-catalytic polypeptide-like (A3G) (APOBEC3G) provokes G to A 
mutation on viral genome (Ross SR, 2009). Despite the fact that the HIV Vif 
protein can prevent A3G, data suggest that A3G may play a role in altering 
the natural course of HIV infection. 
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Among the other members of APOBEC family, one of APOBEC3H 
haplotype, Hap I is associated with protection from sexually transmitted HIV-
1 infection. Hap I carries a protein-destabilizing variant as well as a residue 
conferring resistance to Vif-mediated degradation (Cagliani et al., 2011). 
Candidate gene approaches have also been used to investigate 
polymorphisms in genes directly involved in the immune response to the 
virus. More remarkable results stemmed from the study of TLRs for bacteria 
and viruses. Interestingly, stimulation of PBMCs with agonists specific for 
TLR3 (poly I: C), TLR4 lipopolysaccharide (LPS), TLR7 (imiquimod), and 
TLR7/8 (ssRNA40) resulted in higher cell responsiveness in HESN 
compared to healthy controls (Biasin et al., 2010). The activation of TLR 
pathway in HESN has recently been associated to an increased expression 
of the full-length form of the adaptor protein MyD88, which acts as an 
intracellular negative regulator of this pathway. Furthermore, recent data 
obtained in two independent cohorts of HESN showed that a common TLR3 
allele (rs3775291, Leu412Phe) confers immunologically-mediated protection 
from HIV-1 infection (Sironi M, et al, 2012) (Figure. 1.5). 
More recently other genes involved in HIV-1 infection and replication have 
been considered in association with resistance to HIV-1 infection; among 
these MX2 and TIM-3 exhibited interesting results. 
 MX2 (myxovirus resistance 2) interferes with viral replication thus 
decreasing nuclear accumulation and integration of viral DNA. Mutations in 
the HIV-1 capsid protein, which is involved in nuclear import, can overcome 
the inhibition of MX2. Therefore it has been hypothesized that MX2 targets 
the viral capsid and that it interacts with other cellular proteins - such as 
Cyclofilin A - which block the nuclear import of HIV-1 (Haller O, 2013; Kane 
M, 2013).  
Population studies have shown that natural selection operated on MX2 
during recent human history: different selective events drove the frequency 
increase of two haplotypes in Asians and Europeans. The European 
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haplotype is tagged by rs2074560. Analyses performed on three 
independent cohorts of HESN showed that the ancestral allele of rs2074560 
protects from HIV-1 infection with a recessive effect (combined p value= 
1.55x10-4). The same allele increases MX2 expression levels in response to 
IFN-α. On the whole, this data exploit evolutionary information to identify a 
novel host determinant of HIV-1 infection susceptibility infection regardless 
of the transmission route (Sironi M et al, 2014). 
TIM-3 (T cell immunoglobulin and mucin domain-containing molecule 3) is 
an immunoglobulin superfamily member encoded in humans by the 
HAVCR2 (hepatitis A virus cellular receptor 2) gene. Initially identified as a 
marker of IFN-γ-producing CD4+ Th1 and CD8+ Tc1 cells (Monney L et al, 
2002), TIM-3 was more recently shown to be expressed by several other 
immune cell types including NK/NTK, macrophages/monocytes, and 
dendritic cells (Freeman GJ, 2010). The protein product of HAVCR2 can 
bind both galectin 9 (Gal-9) and phosphatidylserine (Koguchi K et al, 2006). 
Engagement of TIM-3 by Gal-9 on T cells induces cell death and promotes 
peripheral tolerance (Freeman GJ, 2010). Thus, TIM-3 plays an important 
role in the negative regulation of T-cell mediated responses, and abrogation 
of its signaling increases the secretion of IFN-γ by activated human T cells 
(Koguchi K et al, 2006). Recent evidences have indicated that expression of 
TIM-3 marks a population of exhausted CD8+ T cells during chronic viral 
infection (Freeman GJ, 2010). Specifically, in progressive HIV-1 infection 
TIM-3 defines an abundant population of CD8+ T cells and its expression 
correlates positively with viral load and inversely with CD4+ T cell counts 
(Jones RB et al, 2008). The loss of proliferative activity of HIV-specific TIM-
3-expressing CD8+ cells is partially mediated by the interaction with Gal-9 
on Treg cells and is modulated by HLA-B allelic status (Elahi S et al, 2011).   
In a previous study we have reported that a variant located in the 3′UTR of 
HAVCR2 (rs4704846) has been a target of natural selection in human 
populations and suggested that the selective pressure is accounted for by 
 31 
 
infectious agents (Forni D et al, 2013). In line with this view, a SNP 
(rs3087616) located 62 bp apart and in full linkage disequilibrium with 
rs4704846 (r2 = 1 in Europeans) has recently been shown to act as an 
expression QTL (eQTL) in CD14+ monocytes (Fairfax BP et al, 2014).  
Furthermore, genotyping rs4704846 in three independent cohorts of HIV-1 
exposed seronegative (HESN) individuals with different geographic origin 
(Italy and Spain) and distinct route of exposure to HIV-1 (sexual and injection 
drug use) the minor G allele at rs4704846 was more common in HIV-1 
infected individuals than in HESN, with healthy controls showing 
intermediate frequency. Combination of the three association analyses 
through a random effect meta-analysis revealed no heterogeneity among 
samples (Cochrane's Q, p value = 0.89, I2 = 0) and yielded a p value of 6.8 
×10−4. The minor G allele at rs4704846 was found to increase HAVCR2 
expression after in vitro HIV-1 infection. Thus, a positively selected 
polymorphism in the 3′ UTR, which modulates HAVCR2 expression, is 
associated with the susceptibility to HIV-1 infection (Sironi M et al, 2012). 
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Figure 1.5. Different cohorts that control HIV infection are used to assess the impact of 
hereditable factors on HIV-1 infection and/or progression. One of the genetic correlates of 
protection to HIV infection so far identified by the candidate gene approach is summarized 
herein ((Biasin M, 2013). 
 
 
1.5.3 Immune correlates of protection 
Innate immunity is likely to contribute to protection upon primary exposure to 
HIV in HESN before adaptive responses have developed.  
Accumulating functional evidence supports a role for NK activation in 
resistance to HIV infection (Montoya et al., 2006). Additionally, TLR 
stimulation of Peripheral Blood Mononuclear Cells (PBMCs) with TLR 
agonists resulted in higher cell responsiveness in HESN as demonstrated by 
elevated production of proinflammatory cytokines and chemokines (Biasin at 
al., 2010). 
Secreted factors have also been associated with reducing susceptibility to 
mucosal transmission of HIV. The β-chemokines macrophages inflammatory 
protein (MIP)-1α, MIP-1β and RANTES bind the HIV co-receptor CCR5, 
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thereby reducing HIV infection of target cells by outcompeting the virus for 
receptor usage. Peripheral production of β-chemokines was associated with 
resistance to HIV-1 infection (Tomescu et al., 2011), and elevated salivary of 
β-chemokines were associated with oral sexual behavior in HESN MSM 
(Hasselrot et al., 2010). Elevated IL-22 has also been associated with 
resistance to infection in HESN, and is thought to act by induction of acute–
phase serum amyloid A, which downregulates CCR5 expression on target 
cells (Missè et al., 2007). 
Multiple lines of evidences suggest that HIV-specific T cell responses are 
associated with resistance against HIV infection. HIV-specific T cells have 
been detected in PBMCs from commercial sex workers (CSW), men that 
have sex with men (MSM) discordant couples, occupationally exposed 
healthy care workers, injection drug users-HIV exposed seronegative (IDU-
HESN) and prenatally exposed infants. Both CD4+ and CD8+T cell 
responses have been linked to HIV infection in HESN. HIV-specific CTLs 
have been described in several different HESN cohorts and many authors 
claim that these cells make a fundamental contribution at modulating 
resistance to HIV infection. HIV-specific CTLs have been observed and 
characterized in the Pumwani Kenyan cohort of sex workers both at 
systemic and mucosal levels; in injecting drug users; and in sexual partners 
of HIV-infected patients. These studies analyzed approximately 100 HESN 
individuals; HIV-specific CTLs were observed in the majority (>70%) of such 
HESN. The detection of HIV-specific CTLs in HESN individuals raises 
important scientific questions: only the successful infection of host cells, that 
is, infection resulting in at least one complete cycle of viral replication, allows 
the effective presentation of viral peptides within a binary complex with a 
human leukocyte antigen (HLA) class I molecule. The detection of HIV-
specific CTLs in HESN individuals thus seems to indicate that HIV has 
managed to infect the host, but that its further propagation has been 
contained by immune mechanisms. The recent description of an alternative 
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mechanism of processing and presentation by HLA class I molecules of 
exogenous antigens known as cross-priming could, nevertheless, explain the 
presence of CTLs in HESN individuals in the absence of actual infection. 
According to this mechanism, dendritic cells can process the virus and 
present it to CTL precursors in the absence of viral replication. If this were 
the case, the presence of HIV specific CTLs in HESN individuals would be 
the consequence, not necessarily of an infection, but of a different and 
presumably more efficient processing pathway of HIV antigens within 
dendritic cells. 
In particular, HIV-specific CD8+ CTLs of the HESN individuals recognize HIV 
epitopes that are different from those recognized by cells of HIV-infected 
patients 32 and Gag-stimulated CD8 T lymphocytes isolated from HESN 
individuals are characterized by higher levels of intracellular perforin and 
granzymes than those isolated from the HIV-infected partners (n ¼30 HESN 
individuals studied) (Miyazawa et al., 2009, KAUL). 
HIV-specific IgA have been isolated from the female genital tract (FGT) of 
HESN CSW as well as uninfected partners of discordant couples (Devito et 
al., 2002). However, similar antibodies were not detected in Gambian HESN 
CSW cohort and in Pumwany cohort there were HIV-specific IgA but no 
association was found between HIV-specific IgA and virus neutralization or 
shedding (Horton et al., 2009). 
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1.6. Non- coding RNAs (ncRNAs) 
The term non-coding RNAs (ncRNAs) is usually used for RNAs that do not 
encode a protein, however this does not mean that such RNAs do not 
contain information nor have function, in fact they are molecules with 
biological relevant role. In prokaryotes, ncRNAs demonstrate only small 
proportion of the whole genome, which is generally represented by protein-
coding sequence accounting for 80-95% of it (Mattick, J.S. 2004). In 
contrast, only a minority of the genome is occupied by protein- coding 
sequences in multicellular organisms. Indeed the proportion of ncRNAs rises 
with increasing complexity with an accompanying growth of the number of 
non-coding intergenic and intronic sequences, most of which are absolutely 
transcribed (Frith, M.C., 2005). These differences suggest the presence of a 
revolutionary shift in transcriptional output between micro and multicellular 
organisms from mainly protein-coding mRNAs to mainly non-coding RNAs 
(Mattick, J.S. 2006). As reported by the International Human Genome 
Sequencing Consortium, in the human genome the number of the protein-
coding genes represents a range of 20.000- 25000 and corresponds to only 
2% of the whole genome (International Human Genome Sequencing 
Consortium, 2004) while, the remaining of the human genome, previously 
assumed not to be functional and referred as “junk DNA”, has been recently 
classified as ncRNA (Calore F, 2013).  
NcRNAs can be classified as small (~18–31 nt), medium (~31–200 nt) and 
long (from 200 nt up to several hundred kb) transcripts based on their size. 
The small ncRNAs group includes small interfering RNAs (siRNAs), 
microRNAs (miRNAs, miRs) and Piwi interacting RNAs (piRNAs), while 
medium ncRNAs represented by small nuclear RNAs (snRNAs) and small 
nucleolar RNAs (snoRNAs). Very little is known about the long non-coding 
RNA (lncRNA), which are  not highly conserved at the primary sequence 
level but they have been estimated to be ~17,000 in human and ~10,000 in 
mouse genome.  
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Moreover, ncRNAs can be functionally divided into housekeeping ncRNAs 
such as ribosomal, transfer, snRNAs and snoRNAs which play essential 
roles in many cellular processes, and regulatory ncRNAs such as miRNAs, 
piRNAs, siRNAs and lncRNAs (Da Sacco L, 2012). 
1.7. MicroRNAs 
1.7.1. History of MicroRNAs  
Historically, the small RNA revolution started with the detecting of an 
unexplained silencing phenomenon in floral pigmentation (J. Davidson-
Moncada, 2010). The phenomenon was described “co-suppression” at the 
time, and it is the first example of what is now known as RNA interference 
but the molecular mechanism behind it remained unclear (Romano N, 1992). 
In 1993, the field of miRNA began with the identification in Caenorhabditis 
elegans of the lin-4 microRNA gene by Victor Ambros and his colleagues. 
The authors reported that lin-4, a small RNA hitherto unknown as an miRNA, 
down-regulate expression of lin-14 by antisense complementarity to the 3’ 
untranslated regions (3’UTRs) of lin-14 (Cullen BR, 2004). This kind of RNA 
was then demonstrated not to be an isolated factor limited to nematodes, but 
rather a member of a large family of small regulatory RNA that is extensively 
expressed in many species. Actually, as reported by the microRNA database 
in 2012 (miRBase, www.miRbase.org), 2042 and 1281 mature microRNAs 
are documented in humans and in mice respectively (Kozomara A, 2011).  
MicroRNAs are post-transcriptional regulators of gene expression that 
function by inhibiting translation of mRNAs (Bartel DP, 2004) (Berezikov E, 
2011). They are endogenously encoded single stranded RNAs of 18-22 
nucleotides in length that inhibit mRNA translation through imperfect base-
pairing with sequences, which are generally located in the 3’UTR of mRNA 
transcript (Kim VN, 2006). 
 
 37 
 
1.7.2. Genomics organization of microRNA 
MicroRNA genes are scattered in all chromosomes in humans except for the 
Y chromosome. Most of them are transcribed independently from other 
neighboring genes so they are located in the intergenic regions of the 
genome. These microRNAs can be organized as monocistronic and possess 
their own promoter, or polycistronic (clustered), with a shared promoter. 
(Iorio MV, 2012). 
MicroRNAs are also found in the introns of annotated genes, both protein-
coding and non-coding. Similarly to the intergenic ones, also these 
microRNAs can be present as monocistronic or polycistronic and their 
expression is strictly linked to the transcription of the gene from which they 
originate. Also, some microRNAs proceed from spliced-out introns, and are 
basically equal to the pre-microRNAs and they are therefore called mirtron. 
They often overlap an exon and an intron of a non-coding gene and their 
maturation often excludes host gene function (Olena AF, 2010).  
  
1.7.3. MicroRNA classification and nomenclature 
MiRNA genes compose one of the most numerous gene families, and are 
extensively distributed in animals, plants and viruses. The latest release of 
the miRNA database (miRBase, www.miRbase.org) has classified 1881 
precursors and 2588 mature miRNAs in humans, although the functional 
importance of many of these miRNA remains to be determine (Cammaerts 
S. et al. 2015).  
MicroRNAs that possess identical sequences at nucleotides 2-8 of the 
mature form generally belong to the same “microRNA family”, for example 
the let-7 family, composed of 14 paralogs loci (microRNA sisters) (Bartel DP, 
2009). 
The nomenclature of miRNA genes is somewhat inconsistent. The genes 
detected in initial genetic studies were named after their phenotypes (for 
example, lin-4, let-7 and lsy-6), whilst numerical names were given to most 
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miRNAs found from cloning or sequencing (for example, the lin-
4 homologues in other species are called mir-125). Genes encoding miRNA 
sisters (paralogs) are illustrated with lettered suffixes (for example, mir-
125a and mir-125b). If the same mature miRNA is developed from multiple 
discrete loci, numeric suffixes are added at the end of the names of the 
miRNA loci (for example, mir-125b-1 and mir-125b-2). Each locus generates 
two mature miRNAs: one from the 5′ strand and one from the 3′ strand of the 
precursor, designed as -5p and -3p respectively (for example, miR-223a-5p 
and miR-223a-3p). However, one arm (called the 'guide' strand) is usually 
much more prevalent (96–99% of the sum on average) and more biologically 
active than the other arm (the 'passenger' strand, which is known as 
miRNA*) (Ha M, 2014). Moreover, mature sequences and precursor hairpins 
differ by labeling with “miR” and “mir” respectively.   
 
1.7.4. Biogenesis of MicroRNAs 
MicroRNA genes are commonly transcribed from RNA polymerase II 
promoters and later processed into mature miRNAs through canonical or 
non-canonical miRNA biogenesis pathways (Figure 1.5). During canonical 
miRNA biogenesis, the primary miRNA (pri-miRNA) hairpin is digested to 
precursor miRNA (pre-miRNA) by Drosha, a member of the RNase III family. 
Non-canonical miRNA biogenesis varies at this step that pre-miRNAs are 
developed by mRNA splicing machinery, avoiding the requirement for 
Drosha-mediated digestion in the nucleus. In both pathways, the pre-
miRNAs are exported to the cytoplasm via the nuclear export protein 
exportin 5 and further processed by a second RNase III enzyme, Dicer (Ha 
M and Kim VN, 2014).  
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Figure 1.5: Canonical and non-canonical miRNA biogenesis pathways. In the canonical 
pathway, microRNAs (miRNAs) are typically transcribed by RNA polymerase II to produce 
primary miRNA (pri-miRNA) hairpins, which are then processed by the Drosha–DGCR8 
(DiGeorge syndrome critical region 8) complex to generate precursor miRNAs (pre-miRNAs). 
These molecules are transported by exportin 5 into the cytoplasm, where they are further 
processed by Dicer–TRBP (TAR RNA-binding protein 2) and loaded into Argonaute 2 
(AGO2)-containing RNA-induced silencing complexes (RISCs) to suppress downstream 
target gene expression. miRNAs are also produced though non-canonical pathways, such as 
spliceosome-dependent mechanisms, as shown here. The miRNA biogenesis pathway is a 
tightly regulated process. For example, Drosha is dependent on phosphorylation by glycogen 
synthase kinase 3β (GSK3β) for proper nuclear localization; Drosha regulates DGCR8 
expression by suppressing DGCR8 mRNA; DGCR8 stabilizes Drosha protein; AGO2 is 
hydroxylated by C-P4H and phosphorylated by MAPK-activated protein kinase 2 
(MAPKAPK2), which stabilizes the protein and regulates its localization to processing bodies 
(P-bodies); and TRBP is stabilized by extracellular signal-regulated kinase 1 (ERK1) or ERK2 
phosphorylation. miRNAs themselves are regulated by a number of modifications, including 
uridylation (Ud).( Zhonghan Li & TarqM Rana, 2014, Nat rev). 
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1.7.4.1. Canonical Biogenesis of microRNAs 
1.7.4.1.1. MiRNA Transcription 
RNA polymerases II (pol II) and pol III are the two candidates for long 
primary transcript (pri-microRNA) transcription. Pol II produces the mRNAs 
and some noncoding RNAs, including the snoRNAs and four of the small 
nuclear RNAs (snRNAs) of the spliceosome, whereas pol III produces some 
of the shorter noncoding RNAs, including tRNAs, 5S ribosomal RNA, and the 
U6 snRNA (Ohler et al.2004). Pri-microRNAs are transcribed from non-
coding regions of the genome by RNA pol II and hold the usual properties of 
class II genes transcripts, a 5 ́ m7 G capping structure and 3 ́ poly (A) tails. 
They can be quite long, more than one 1 kb, thus longer than typical pol III 
transcripts (Lee Y, 2004). 
The nuclear Ribonuclease III, Drosha, and the double-stranded RNA-binding 
domain protein DGCR8 (DiGeorge syndrome critical region protein 8) cleave 
the pri-miRNA and liberate a 60–70 nt stem loop intermediate, known as the 
miRNA precursor, or the pre-miRNA (Lee et al., 2002; Zeng Cullen, 2003). 
 
1.7.4.1.2. Nuclear export 
Exportin 5 (Exp5) a member of karyopherin family of nucleocytoplasmic 
transport factors, can recognize the pre-microRNAs and moreover, it serves 
as a nuclear export factor and is able to protect the pre-microRNA from 
digestion by nucleases (Yi R, 2003). 
The exportins possess a RanGTP-binding site which circulate between 
nucleus and cytoplasm, and transfer cargo molecules from one side of the 
nuclear to the other. Exportins bind their cargoes at high RanGTP levels in 
the nucleus (Fornerod et al. 1997) and translocate as trimeric RanGTP-
exportin-cargo complexes to the cytoplasm, where cargo and Ran are 
released upon GTP hydrolysis. The exportins can then return to the nuclear 
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compartment and mediate another round of transport ((Mattaj and Englmeier 
1998). The presence of a >14-nt stem region along with a short 3 ́overhang 
(1-8 nt) is a crucial requirement for pre-microRNA to be recognized by Exp5 
(Gwizdek C, 2003).  
Once in the cytoplasm, the pre-miRNA hairpin is further processed by Dicer, 
another type III RNase that produces a 22-nucleotide miRNA duplex 
consisting of a 5p–3p strand. This final processing by Dicer is coupled to 
assembly of one of the two strands of the miRNA into the RNA-induced 
silencing complex (RISC) (Alwin Köhler, 2007).  
 
1.7.4.1.3. Guide strands and passenger strands 
Initially, it was proposed that one strand of RNA duplex remains in 
association with Argonaute proteins (Ago), the components of miRISC, as a 
mature miRNA (the guide strand or miRNA), whereas the other strand (the 
passenger strand or miRNA*) is degraded. But, later the importance of 
passenger strands was shown in some studies thus suggesting that the 
passenger strand can be actively incorporated into the miRISC and works as 
well. Therefore, it is not so accurate to use the name ‘passenger strand or 
miR*’ in these cases and it would be preferable to use a nomenclature rule 
which is based on the 5p–3p system since that does not prefer one strand 
over the other. Indeed, for many miRNAs, both strands are readily detected. 
Expression profiling shows that in some tissues, both strands can be equally 
abundant, whereas in other tissues there is a strong preference for one of 
the strands (Meijer HA, 2014). The exact mechanism for strand selection is 
not fully understood. Studies demonstrate that the relative thermodynamic 
stability of the two ends of the duplex indicates which strand is to be chosen. 
The strand with relatively unstable base pairs at the 5 ́end usually remains in 
the miRISC (for example, G:U pair versus G:C pair) (Kim VN, 2005). 
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1.7.4.1.4. Assembly of MicroRNAs into miRISC complex (RLC) 
Following the Dicer processing, mature microRNAs are incorporated into 
effector complexes known as ‘miRNP’ (miRNA-containing ribonucleoprotein 
complex), ‘mirgonaute’ or ‘miRISC’ (miRNA-containing RNA-induced 
silencing complex) (Kim VN, 2005). 
The miRISC complex contains dsRNA binding proteins, including protein 
kinase RNA activator (PACT), transactivation response RNA binding protein 
(TRBP), Dicer and Argonaute (Ago) (Andrew D. Redfern et al, 2013). The 
main component of miRISC complex is Ago protein but all the other proteins 
were illustrated to be involved in strand selection. Four different Ago proteins 
have been identified and each of them is able to bind endogenous 
microRNAs, but only Ago2 exerts endonuclease activity to cleave 
complementary target mRNA sequences (Meister G, 2013). After micro RNA 
is loaded into the miRISC complex, the 2 – 8 nucleotides of the microRNA 
consist of the seed sequence recruit Ago protein to target mRNAs. If the 
base-pairing between miRNA and the 3′ UTR of the target mRNA is perfect 
the messenger is cleaved and degraded, whereas imperfect 
complementarity will result in translational silencing without mRNA 
degradation (Calore F, 2013). 
 
1.7.4.2. Non-canonical Biogenesis of microRNAs 
1.7.4.2.1. Drosha‐independent pathways 
The mirton pathway is the most important Drosha-independent microRNA 
biogenesis mechanism. The distribution of intron length has a sharp peak at 
around 60 nt in Drosophila and Caenorhabditis elegans, which is 
comparable to the size of pre-miRNAs. These Drosophila small RNAs 
originate from pre-miRNA-sized short introns with hairpin potential and 
termed “mirtrons”. They can be spliced and disbranched into pre-miRNA 
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hairpins that are applicable for Dicer cleavage, thus bypassing the 
Microprocessor (Keita Miyoshi, 2010).  
The first spliced intron product is not linear, but instead it is a lariat in which 
the 3’ branch point is ligated to the 5’ end of the intron. However, following 
resolution of this structure by lariat debranching enzyme (LDBR), the intron 
can adopt a pre-miRNA fold and be exported to the cytoplasm via Exportin-5 
and later cleaved by Dicer to load into Ago for target regulation (Jakub O, 
2011).  
 
1.7.4.2.2. Dicer‐independent pathways 
Recently functional microRNAs with ability to bypass dicer activity have been 
discovered. Processing of the pre-miR-451 homologs from human, mouse, 
and zebrafish, has been shown to be independent of Dicer cleavage and 
occur by Ago2 slicer catalytic activity (Jr-Shiuan Yang, 2011). 
At first, pri-mir-451 is cleaved by Drosha/DGCR8 to develop a short pre-
microRNA with only~18 bp of duplex stem so too short to serve as a Dicer 
substrate. Instead, pre-mir-451 is loaded directly into Ago proteins. Ago2 
binds the microRNA and cleaves the paired passenger strand 10 nt away 
from the 5’ end of the Ago2 bound microRNA guide strand (Liu YP, 2013). 
Therefore, Ago2 has not only the cleavage capability of the complementary 
mRNA targets, but also the slicer activity on pre-microRNAs for the 
generation of functional mature microRNAs. 
 
1.7.5. Principles of microRNA-mRNA interaction 
The mechanistic details of the function of microRNAs in repressing protein 
synthesis are still poorly understood. MiRNAs may act through several 
mechanisms including translational repression, inhibition of translation 
initiation, inhibition of translation post-initiation and induction of mRNA 
destabilization and decay (Olsen, P. H. 1998) (Figure 1.6). 
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In plants, miRNAs generally base pair to mRNAs with nearly perfect 
complementarity. With few exceptions, a similar mechanism is used by 
vertebrate and viral miRNAs. However, in most cases, metazoan miRNAs 
pair imperfectly with their targets (Doench, J. G. 2004). Indeed, Binding of 
the miRISC complex to mRNA is mediated by a sequence of 2–8 nucleotides 
at the 5′ end of the mature miRNA, known as the seed region which is 
fundamental for selection of target mRNA (Lewis, B. P., 2005). However, the 
presence of non-canonical sites both in the 5’UTR and in the coding 
sequence (CDS) of mRNAs has been shown (Liu C, 2013). The perfect or 
imperfect complementarity interaction between the seed sequence and 
3’UTR of target mRNA results in mRNA degradation or translational 
inhibition. 
The mechanisms of microRNA-mediated repression are not completely 
understood. Translationally inactive eukaryotic mRNAs usually assemble 
into repressive miRISC that accumulate in cytoplasmic foci known as 
processing bodies (P-bodies, PBs) or GW-bodies for storage or mRNA 
decay (Sheth U, 2003). P-bodies are enriched in proteins that are involved in 
mRNA catabolism (deadenylation, decapping and mRNA degradation) and 
translational repression such as the mRNA decapping enzymes Dcp1/Dcp2, 
the 5’ – 3’ exonuclease Xrn1 (Eulalio, A., 2007) and the key P-/GW-body 
subunit, GW182 (Parker, R. 2007). They are highly dynamic structures, 
fluctuating in size and number during the cell cycle and in response to 
changes in the translational status of the cell.  
Several recently published papers provide important mechanistic insights 
into translational repression both at the initiation step and at the post-
initiation step (Filipowicz W, 2008). Two different models have been 
proposed for microRNA-mediated repression of translation at the initiation 
step. In the first model, it was suggested that microRNAs could hinder 
eukaryotic translation initiation factor 4E (eIF4E) recruitment to the mRNA 
5`-terminal 7 methylguanosine- cap (m7G cap), therefore inhibiting the 
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activity of this crucial translation initiation factor and the consequent access 
to mRNA by the translation machine (Pillai RS, 2005). In this model human 
Ago2 precisely binds to m7G cap by its cap-binding motif similar to that one 
of eIF4E.  
An alternative mechanism for miRNA action was proposed by Chendrimada 
et al. (Chendrimada, T. P. et al, 2007). In this model miRISC complex 
prevents the premature association of 60S with 40S ribosomal subunits by 
recruiting eIF6. Therefore, eIF6 and 60S ribosomal subunit proteins, co-
immunoprecipitate with the AGO2–Dicer–TRBP complex and block the 
assembly of 80S ribosomal complex on target mRNA so, stop the translation 
initiation (Chendrimada, T. P. et al, 2007).    
In addition to target the translation initiation, miRNAs can hinder translation 
at the post –initiation steps, in which miRNAs promoting ribosomes to drop 
off from mRNAs to premature termination of translation (Petersen, C. P. 
2006). 
Moreover, microRNAs could recruit GW182 to miRNA targets through direct 
interactions with Argonaute proteins and promote deadenylation of the poly-
(A) tail of the target mRNA. Although the precise mechanism is not fully 
understood, GW182 proteins have been shown to interact with the 
cytoplasmic poly (A)-binding protein (PABP) followed by the decapping of 
the m7G cap and subsequent mRNA decay (Fabian MR, 2009). 
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Figure.1.6. a | Repression of translation initiation. MicroRNA (miRNA)-mediated silencing 
complexes (miRISCs) inhibit the initiation of translation by affecting eukaryotic translation 
initiation factor 4F (eIF4F) cap recognition, 40S small ribosomal subunit recruitment and/or by 
inhibiting the incorporation of the 60S subunit and the formation of the 80S ribosomal 
complex. Some of the target mRNAs bound by the miRISC are transported into processing 
bodies (P-bodies) for storage and may re-enter the translation phase when induced by 
exogenous signals such as stress. b | Post-initiation translational repression. miRISCs may 
inhibit the elongation of ribosomes, causing them to drop off the mRNAs and/or facilitate the 
degradation of newly synthesized peptides. c | Destabilization of target mRNAs. Binding of 
miRISCs to target mRNAs may recruit RNA decapping and/or deadenylating enzymes that 
lead to mRNA destabilization. P-bodies are the key cellular organelles for the degradation and 
storage of targeted mRNAs. AGO2, Argonaute 2; DCP1, mRNA-decapping enzyme 1; PABP, 
poly(A)-binding protein.( Zhonghan Li & Tariq M. Rana, 2014, Nat rev). 
 
 
 
 
 
 
 47 
 
1.7.6. Multistep regulation of microRNA biogenesis 
Dysregulation of both miRNA biogenesis and function is usually combined 
with human disease, so it is not surprising that both these mechanisms are 
subjected to a narrow control. 
1.7.6.1. Transcriptional regulation. 
MiRNA transcription is carried out by RNA Pol II and is controlled by RNA 
Pol II-associated transcription factors and epigenetic regulators (Cai, X., 
2004). Exact locations of the miRNA promoters have not yet been identified 
for most miRNA genes, some miRNA genes reside in the introns of protein-
coding genes and, thus, share the promoter of the host gene. Also, miRNA 
genes often have multiple transcription start sites (Ozsolak, F. et al. 2008) 
and the promoters of intronic miRNAs are sometimes distinct from the 
promoters of their host genes (Monteys, A. M. et al. 2010). So far some 
transcription factors have been found, such as p53, V-Myc Avian 
Myelocytomatosis Viral Oncogene Homolog (MYC), Zinc Finger E-Box 
Binding Homeobox 1 (ZEB1) and 2 (ZEB2), and myoblast determination 
protein 1 (MYOD1) which positively or negatively regulate miRNA expression 
(Krol, J., 2010). Epigenetic control, such as DNA methylation and histone 
modifications also contribute to miRNA gene regulation.  
1.7.6.2. Drosha and Dicer processing regulation 
There are different positive and negative processing factors that can alter 
miRNA biogenesis for instance, multiple mechanisms exist to control the 
expression level, activity and specificity of Drosha. The efficiency of Drosha-
mediated processing is essential for determining miRNA abundance. Post-
translational modifications can determine the protein stability, nuclear 
localization and processing activity of the Microprocessor. For instance, 
phosphorylation of Drosha by glycogen syntetase kinase 3 (GSK3) is 
necessary for nuclear localization of Drosha (Tang X, 2010) and acetylation 
of Drosha by unidentified enzyme inhibits its degradation (Tang X, 2013). 
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Also, modifications on DGCR8 can influence the activity of the 
Microprocessor.  
Moreover, RNA-binding proteins that selectively interact with Drosha and/or 
certain pri-miRNAs can control the Drosha-mediated processing including 
the helicases p68 (also known as DDX5) and p72, and receptor-activated 
SMAD proteins (R-SMADs) (Ha M, Kim VN, 2014). For instance, Drosha –
mediated processing of miR-21 and miR-199a is stimulated by R-SMADs 
interaction with p68 and the stem of pri-microRNAs (Davis BN, 2008). 
Some proteins can bind selectively to the terminal loop of pri-miRNA and 
affect the post transcriptional process, including heterogeneous nuclear 
ribonucleoprotein A1 (HNRNPA1) which promotes Drosha binding to the pri-
microRNA, and the KH-type splicing regulatory protein (KSRP or KHSRP), 
which facilitates both Dicer- and Drosha- mediated processing (Ha M, Kim 
VN, 2014). Furthermore, Dicer cofactors including TRBP and AGO proteins 
are subject to post transcriptional modifications which influence their ability 
to regulate Dicer processing, RISC formation and miRNA activity. 
 
1.7.6.3. MiRNA intrinsic regulation 
There are many different ways to introduce changes in RNA molecule and 
these alterations in sequence and/or structure can affect the maturation and 
turnover of miRNAs. For instance, the conversion of adenosine to inosine (A-
to-I) RNA editing, catalyzed by adenosine deaminases (ADAR) enzymes on 
specific pri-microRNAs determines the destiny of mature microRNAs in 
several ways. The processing of certain miRNAs can be inhibited by A-to-I 
editing in the hairpin region at Drosha and Dicer level and modify the miRNA 
biogenesis (Yang W, 2006). 
Also, the presence of single nucleotide polymorphisms (SNPs) in miRNA 
genes can sometimes affect their biogenesis and/or change their target 
specificity (Ryan, B. M, 2010). For example, a C to T SNP in the first C of the 
CNNC motif in pri-miR-15a~16-1 reduces Drosha-mediated processing and 
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thereby lowers miR-16 production (Auyeung, V. C, 2013). Regulation 
through RNA tailing process which is adding untemplated nucleotididyl to the 
3’ end of RNA also can modify pre and mature miRNA to facilitate or inhibit 
miRNA decay (Heo I et al, 2008). Uridylation of the let-7 precursor (pre-let-7) 
has been most extensively studied. In that case LIN28 proteins induce 
terminal uridylyl tranferases TUT4 and TUT7 to enhance oligouridylation of 
pre-let-7 blocking Dicer processing and recruiting exonucleases that 
recognize the U-tail determining microRNA decay (Heo I et al, 2008).  
Although so far very little is known about miRNA stability, the regulation of 
microRNAs turnover could be essential for their abundance in the cell 
(Ruegger, S. & Grosshans, H. 2013). Several nucleases have been 
proposed to cleave and degrade miRNAs, but it is unknown how they 
achieve substrate specificity and whether there is conserved machinery for 
miRNA decay. For example in C. elegans, degradation of unprotected 
mature microRNAs is performed by the 5’–3’ exoribonuclease 1 and 2 (XRN-
1 and 2) (Chatterjee S, 2009).  
Moreover, it has been shown that the target mRNA can modulate the 
stability of miRNAs. Highly complementary targets induce miRNA 
degradation accompanied by tailing and trimming (Ameres, S. L. et 
al.  2010). By contrast, it has been reported in C. elegans that miRNAs are 
stabilized by their targets (Chatterjee S, 2009).  Thus, further investigation is 
required to understand the mechanisms and physiological importance of 
target-mediated stability control. 
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1.8. Immune system and MicroRNAs 
The immune system provides a complex but well-orchestrated defense 
mechanism against several pathogens. An infection may trigger an 
inflammatory response whose initiation, proliferation and resolution must be 
carefully coordinated and balanced. Lack of proper initiation or proliferation 
prevents the innate immune response; conversely, lack of suitable resolution 
can point to chronic disease states. Therefore, the immune response (both 
innate and adaptive) is extremely regulated and as recently demonstrated 
such control is largely dependent on micro-RNAs activity (Jan Davidson-
Moncada, 2010). 
MiRNAs in general participate in regulatory networks that control T cell 
activation, the expansion of the T cell population and effector T cell 
differentiation. MiRNA-deficient CD4+ T cells showed a surprising increase in 
effector Th cell differentiation and cytokine production which indicates a key 
role for miRNAs in the maintenance of the naive T cell state (Muljo, S. A. et 
al. 2005).  
Some miRNAs down-regulate T cell activation such as miR-29 which hinder 
the differentiation of particular Th cell subsets (Steiner, D. F. et al. 2011) or 
miR-125, seems to inhibit effector T cell differentiation in general. miR-125b 
is highly expressed in human naive CD4+ T cells compared with various 
memory T cell populations, and it inhibits the expression of several genes 
involved in T cell differentiation, including IFNɣ, IL2RB, IL10RA (Rossi, R. L. 
et al, 2011). 
One of the regulators of TCR signaling is miR-181 family that has important 
effects on T cell development and homeostasis. The inhibition of miR-181 in 
thymocytes reduces TCR sensitivity and diminishes positive and negative 
selection in the thymus. Conversely, the overexpression of miR-181a in 
mature T cells augments their sensitivity to peptide antigens in the periphery 
(Li, Q. J. et al. 2007).  
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Another essential miRNA in the regulation of TCR pathway is miR-146a 
which is a critical feedback regulator of nuclear factor-κB (NF-κB) signaling. 
It is abundantly expressed in human memory T cells and NF-κB p50 (also 
known as NFKB1) can further induce its expression following TCR 
engagement (Rusca, N. et al. 2012).  
Some MiRNAs can mediate essential role in regulation of T cell proliferation 
and survival. The miR-17~92 cluster regulates various aspects of T cell 
activation as well as the consequent fate of the activated T cells and it 
comprises six miRNAs from four miRNA families. CD4+ and CD8+ T cells can 
express this miRNA cluster and the related miR-106a~363 and 
miR-106b~25 clusters (Bronevetsky, Y. et al, 2013). The overexpression of 
miR-17~92 in T cells causes lymphoproliferation and an autoimmune-like 
disease characterized by increased serum antibody levels and an increased 
production of autoantibodies (Xiao, C. et al. 2008) (Mogilyansky E, 2013). T 
cell proliferation can be enhanced in the absence of both miR-17 and 
miR-92. MiR-19, another miR-17~92 cluster member, positively regulates 
the survival of activated T cells. These miRNAs mediate their effects 
targeting directly many genes such as Pten and the pro-apoptotic 
BCL-2-interacting mediator of cell death (Bim; also known as Bcl2l11) (Xiao, 
C. et al. 2008).  
Another phosphatidylinositol phosphatase, SH2 domain-containing inositol 
polyphosphate 5ʹ phosphatase 1 (Ship1; also known as phosphatidylinositol 
3,4,5-trisphosphate 5-phosphatase 1), is a validated direct target of miR-155 
(Loeb, G. B. et al, 2012), highly induced following TCR stimulation (Thai, T. 
H. et al. 2007). miR-155 deficiency decreases T cell-dependent humoral and 
cellular immune responses, probably as a result of the absence of its activity 
on several mRNA targets (Thai, T. H. et al. 2007) (Vigorito E, 2013). Finally, 
miRNAs can have powerful effects on biological processes by regulating 
genes that control signaling thresholds. Several miRNAs function at multiple 
levels to regulate the development, the homeostasis and the activation of T 
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cells. These effects have important consequences on T cell function, and 
they are complemented by the miRNA-mediated regulation of particular T 
cell differentiation pathways and effector mechanisms (Figure 1.7). 
 
   
 
 
Figure .1.7. a | MicroRNAs (miRNAs) are important regulators of effector T cell 
differentiation, including T cell activation, proliferation and the acquisition of effector functions 
such as cytokine production (left panel). The genetic ablation of key molecules of the miRNA 
biogenesis pathway in CD4+ T cells highlighted the importance of miRNAs in these 
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processes. The activation of miRNA-deficient CD4+ T cells results in increased and aberrant 
cytokine production and decreased cell proliferation (right panel).  
b | A mechanistic overview of the participation of miRNAs in regulatory networks that control 
T cell activation, the expansion of the T cell population and effector T cell differentiation is 
shown. The T cell receptor (TCR) signalling cascade activates nuclear factor of activated T 
cells (NFAT) and nuclear factor-κB (NF-κB), both of which induce the upregulation of miR-
155 expression. miR-155 targets SH2 domain-containing inositol polyphosphate 5′ 
phosphatase 1 (Ship1) and suppressor of cytokine signalling 1 (Socs1), and promotes T cell 
activation and population expansion. NF-κB signalling also induces the expression of miR-
146a, which inhibits T cell activation and population expansion through a negative feedback 
loop involving the miR-146a target genes TNF receptor-associated factor 6 (Traf6) and 
interleukin-1 receptor-associated kinase 1 (Irak1). Mammalian target of rapamycin (mTOR) 
signalling results in accelerated miRNA turnover and promotes T cell survival and 
proliferation partly through MYC-induced miR-17~92 expression. The high levels of 
expression of miR-125b in human naive CD4+ T cells impede T cell differentiation by 
repressing T cell effector genes, including interferon-γ (IFNG), IL2RB and PRDM1 (the gene 
encoding B lymphocyte-induced maturation protein 1 (BLIMP1)). The downregulation of 
inhibitory phosphatases such as dual-specificity protein phosphatase 5 (Dusp5), Dusp6, 
protein tyrosine phosphatase non-receptor type 22 (Ptpn22) and SH2 domain-containing 
protein tyrosine phosphatase 2 (Shp2) by miR-181a increases TCR signalling. IL-2-induced 
miR-182 expression interferes with T cell population expansion by targeting the transcription 
factor forkhead box protein O1 (Foxo1). It is worth noting that specific miRNAs are both 
regulated targets and upstream regulators of signalling pathways that control T cell 
behaviour. AGO2, Argonaute 2; Bim, BCL-2-interacting mediator of cell death; DC, dendritic 
cell; Pten, phosphatase and tensin homologue. (Dirk Baumjohann and K. Mark Ansel, 2013, 
Nat rev. 
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1.9. HIV-1 and MicroRNAs 
MiRNAs are related to a plenty of pathological and physiological pathways in 
mammalian systems. For instance, the dysregulated expression of miRNAs 
and other RNAi components has been defined in cancers, metabolic 
disorders, and infectious diseases (Yeung M. L., Jeang K. T. 2011). In 
plants, RNAi serves as a host defense mechanism against viral infections 
(Pantaleo V.  2011). In mammals, the role of RNAi in regulating viral 
infection is less clear; however, recent studies showed the critical role of 
miRNAs in several viral infections, with different viral families expressing 
their own miRNAs, manipulating host miRNA expression, or displaying direct 
or indirect regulation by host or viral miRNAs (Roberts, et al. 2011). 
The interactions between HIV-1 and the host cellular miRNAs have been 
studied, if not extensively, at least in some detail. However, it still remains a 
quite complex issue. It has been suggested that certain host cellular miRNAs 
can restrict HIV-1 replication and this in turn may play vital roles in host 
defense and in maintaining latency within resting CD4+ T cells. Conversely, 
host cellular miRNAs have also been indicated to be fundamental for certain 
viruses to establish infection and different expression of cellular miRNAs in 
HIV-1 infected cells may also be a factor favoring viral replication (Sanjay 
Swaminathan, 2012). 
MiRNAs involved in HIV-1 infection could be categorized as host-encoded 
(Cellular miRNAs) or HIV-1-encoded based on their source of biogenesis; or 
defined as suppressors or activators of HIV-1 infection based on their 
function. Also, they can be divided according to whether they directly or 
indirectly target HIV-1 transcripts by targeting host factors that are involved 
in the HIV-1 life cycle. An overview of the modulation of HIV-1 replication by 
cellular miRNAs is presented in figure 1.8 and table 1.1. 
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Figure 1.8. Cellular miRNAs may modulate HIV-1 infectivity and replication. HIV-1 infection 
can be directly affected by cellular miRNAs that can target HIV-1 viral RNA through base pair 
complementarity (indicated in green). In addition, other miRNAs can inhibit host proteins that 
play an active role during productive HIV-1 infection and thereby indirectly inhibit HIV-1 
replication (indicated in red). More recently, few miRNAs that can enhance HIV-1 infection 
have also been identified (indicated in blue). The mechanisms underlying these pro-HIV-1-
miRNAs have not been well defined, but it is possible that these miRNAs can bind to and 
suppress negative regulators of HIV-1 infection. Finally, HIV-1-encoded vmiRNAs such as 
HIV1-miR-H1 and TAR-miRNA might also modulate viral infectivity. Further research is 
needed to elucidate the specific mechanisms by which these vmiRNAs and many cellular 
miRNAs might affect HIV-1 infectivity and replication (Gokul Swaminathan et al. 2014, J. Mol. 
Biol). 
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1.9.1. Cellular miRNAs Regulate HIV-1 Expression 
1.9.1.1. MiRNAs that directly target HIV-1 
HIV-1 infection can be directly affected by cellular miRNAs that can target 
HIV-1 viral RNA through base pair complementarity (Fig. 1.8 and Table 1.1.).  
At first, Hariharan et al tried to search for cellular miRNAs that directly target 
sites in the HIV genome by using target prediction software (Hariharan et al, 
2005). They determined five miRNAs (miR-29a, miR- 29b, miR-149, miR-
324-5p, and miR-378) target sites in the HIV-1 genome with two of them 
located in the viral nef gene (Hariharan et al, 2005). Later, one of the five 
identified miRNAs (miR-29a) was confirmed to inhibit nef expression, thus 
blocking HIV replication in Jurkat cells (Ahluwalia J.K. et al. 2008). Recently 
Sun et al. reported that miR-29a and miR-29b can inhibit the HIV-1 infection; 
however, miR-29 access to HIV-1 is restricted by the complex RNA 
secondary structure surrounding the target site (Sun et al, 2012). 
In this sense, a selected group of miRNA was illustrated to play an active 
role in modulating HIV-1 infectivity of resting CD4+ T lymphocytes (Huang et 
al, 2007). Huang et al showed that 5 different cellular miRNAs, including 
miR-28, miR-125b, miR-150, miR-223 and miR-382, had the ability to bind to 
the 3′ UTR of viral mRNAs through sequence complementarity. They also 
demonstrated the down regulation of these miRNAs as result of activation of 
resting CD4+ T cells, which correlated with enhanced HIV-1 susceptibility. 
Furthermore, it was proposed that translational repression is largely 
responsible for HIV-1 latency in resting CD4+ T cells mediated by these “anti-
HIV-1 miRNAs” (Huang et al, 2007) (Cobos Jimenez V, 2012).  
Modulation of these anti-HIV-1 miRNAs can change HIV-1 infectivity in 
response to various stimuli for instance, cytokines and TLR ligands. It has 
been shown that the stimulation of TLR3 can induce an anti-HIV-1 effect in 
primary macrophages, partially through up-regulation of the set of anti-HIV-1 
miRNAs mentioned above (Zhou Y. et al. 2010). Interestingly, up-regulation 
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of miR-28, miR-125b, miR-150 and miR-382 were also reported in 
macrophages treated with IFN-α and IFN-β, and was shown to partially 
contribute to inhibition of HIV-1 infection in primary macrophages (Cobos V. 
Jimenez et al. 2012). 
Later, Wang et al. reported that this group of anti-HIV-1 miRNA was enriched 
in monocytes as compared to monocyte-derived macrophages and 
responsible for differences between monocytes and macrophages in their 
permissivity to HIV infection (Wang et al, 2009) (Wang X, 2011). They 
showed that these miRNAs were down regulated upon macrophages 
differentiation and that this down-regulation was associated with their 
capacity to support productive HIV-1 infection. However, more recently Sisk 
et al. published new results which only confirmed the down regulation of 
miR-223 in macrophages, while the other previously mentioned mirnas were 
either more abundant or unchanged in macrophages compared to 
monocytes (Sisk et al, 2012).  
Furthermore, four new miRNAs (miR-133b, miR-138, miR-149, and miR-
326) have been identified to target HIV-1.  Houzet et al. were able to confirm 
the action of miR-29 as an anti-HIV miRNA (Houzet et al 2012). 
Taken together, the findings suggest that, in divergent cells and in varying 
contexts, different miRNAs may selectively regulate HIV-1 infection through 
direct targeting of viral sequences. 
1.9.1.2. MiRNAs that indirectly target HIV-1 
Various groups have determined many host factors that seem to be 
necessary or at least to participate to a certain extent in, one or more steps 
of the viral life cycle by genome wide screenings (Brass A.L., 2008) 
(Bushman F.D., 2009). Since miRNAs play such an important role in 
modulating cellular protein expression, it is reasonable that miRNAs may 
regulate HIV-1 infection, indirectly, through the modulation of the levels of 
HIV dependency factors (HDFs). 
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One of the important components of eukaryotic RNA polymerase II 
elongation complex is cyclin T1 in association with cyclin-dependent kinase 
9 (CDK9) and transcription elongation factor B (p-TEFb) (Zhou Q., Yik J.H., 
2006) (Chiang K, 2012).  
Many studies have described p-TEFb complex interaction with HIV-1 TAR 
factor and the viral protein Tat to facilitate viral transcription (Hoque M., 
2011) (O'Keeffe B., 2000).  
Sung et al. proposed an anti-HIV-1 role for miR-198 which targets the cyclin 
T1 mRNA; at first they detected a negative correlation between cyclin T1 
levels and miR-198 in monocytes and macrophages: subsequently, miR-198 
binding to the 3` UTR of cyclin T1 mRNA was reported and demonstrated to 
reduce its protein level (Sung et al, 2009). Moreover, the same authors 
showed that miR-198 over-expression hindered HIV-1 replication in 
macrophages, supporting the idea that miRNAs apply cell-type-specific 
effects (Sung et al, 2009). It has been shown that miR-198 is expressed at 
very low levels in resting CD4+ T cells and is not modulated upon 
activation (Chiang et al. 2012). Chiang et al. also detected other miRNAs 
capable to regulate cyclin T1 expression (e.g. miR-27b, miR-29b, miR-223, 
and miR-150), potentially explaining expression differences of HIV in resting 
versus activated T cells. They reported that the down regulation of these 
miRNAs, is a consequence of CD4+ T cells activation and correlates with a 
Cyclin T1up-regulation and enhanced HIV-1 susceptibility (Chiang et al. 
2012).  
Independently, another group found that miR-17-5p and miR- 20a can target 
p300/CBP associated factor (PCAF), another cellular cofactor of the viral Tat 
protein. Specifically, the over-expression of miR-17-5p and miR- 20a 
resulted in decreased mRNA levels and protein output of PCAF. Of note, 
HIV-1 infection actively suppressed these miRNAs to augment its infectivity 
by arrogating the p300/PCAF complex for efficient viral translation (Triboulet, 
R. 2007). 
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Furthermore, six miRNAs (miR- 15a, miR-15b, miR-16, miR-20a, miR-93, 
and miR-106b) were found to target purine-rich element binding protein α 
(Pur-α) mRNA. Pur-α protein is a sequence-specific DNA and RNA binding 
protein which facilitates viral transcriptional up-regulation by binding to the 
HIV-1 TAR component and viral Tat protein in the nucleus of infected cells 
(Gallia GL et al. 1999) (Shen CJ, 2012). In a recent study, higher expression 
levels of miR-15a, miR-15b, miR-16, miR-20a, miR-93 and miR-106b was 
associated with significantly lower expression of Pur-α and lower 
susceptibility to HIV-1 infection in monocytes compared with monocyte-
derived DCs (Shen CJ et al, 2012). 
Targeting	 miRNAs Target	 Function	
DIRECT	
miR‐29a  Nef  Decrease HIV infectivity 
miR‐28 
miR‐125b* 
miR‐150 
miR‐223 
miR‐382 
3’ LTR 
Latency in primary resting 
CD4+ T cells 
 
Restrict HIV‐1 replication in 
monocytes 
miR‐133b 
miR‐138 
miR‐149 
miR‐326 
3’ LTR**  Decrease HIV replication 
INDIRECT	
miR‐17‐5p 
miR‐20a  PCAF  Decrease HIV replication 
miR‐198  Cyclin T1  Restrict HIV‐1 replication in monocytes 
miR‐27b  Cyclin T1   
miR‐29b 
miR‐150 
miR‐223 
Cyclin T1***  Restrict HIV‐1 replication in resting CD4+ T cells 
miR‐15a 
miR‐15b 
miR‐16 
miR‐20a 
miR‐93 
miR‐106b 
Pur‐α  Restrict HIV‐1 replication in monocytes 
Table 1.1. miRNAs involved in the regulation of HIV-1 expression. 
* miR-125b was involved in HIV-1 restriction in resting T cells only.  
** This study specifically examined only the miR-326 target site.  
*** Indirect regulation of cyclin T1 by miR-29b, miR-150, and miR-223. (Zachary Klase et al. 
JBC, 2012) 
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1.9.1.3. MiRNAs that enhance HIV-1 infection 
Very few studies have reported miRNA-mediated enhancement of HIV-1 
infection however, recently HIV-1 infection was shown to be increased by 
miR-132 (Chiang K, Liu H, Rice AP, 2013). Activated CD4+ T cells were 
reported to have significantly higher miR-132 expression and also ectopic 
miR-132 expression in Jurkat T cells was shown to increase HIV-1 infection 
(Chiang K, Liu H, Rice AP, 2013). However, the mechanisms underlying 
this effect are not completely clear. Preliminary data showed that miR-132 
overexpression decreased the expression of a cellular protein MeCP2, a 
methyl CpG binding cellular protein. siRNA- mediated inhibition of MeCP2 
can enhance HIV-1 replication, however, the specific role of miR-132 and 
MeCP2 in HIV-1 replication has not been identified (Leoh LS et al. 2012).  
In another study, sirtuin 1 (SIRT1) was shown to mediate regulation of HIV-
1 Tat transactivation. SIRT1 is a class III deacetylase dependent on 
nicotinamide adenine dinucleotide that can regulate HIV-1 transcription by 
deacetylating Tat (Pagans S et al, 2005). In a recent study, significant up-
regulation of miR-217 and miR-34a was detected upon Tat exposure and it 
was shown that they have the ability to bind the 3′ UTR region of SIRT1 
mRNA and hinder its expression, so increasing HIV-1 Tat-mediated 
transactivation (Zhang HS, 2012). 
 
1.9.2. HIV-1-encoded MiRNA 
Certain families of viruses encode their own miRNAs known as viral miRNA 
or vmiRNAs which can influence viral replication (Kincaid and Sullivan, 2012; 
Nair and Zavolan, 2006). The majority of vmiRNAs belong to DNA viruses, 
while the expression of functional vmiRNAs by retroviruses, especially HIV-
1, remains controversial. Through bioinformatic prediction algorithms, 5 
candidate vmiRNAs (Bennasser et al., 2004) were predicted to be encoding 
by the HIV-1 genome. Moreover, vmiRNA (Nef-U3-miR-N367) was found in 
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the HIV-1 Nef coding region (Omoto and Fujii, 2005; Omoto et al., 2004) 
and, the 3′ end of the HIV-1 RNA was shown to encode for another vmiRNA: 
HIV-1-miR-H1 (Kaul et al., 2009) (Zhang Y, 2014). While these studies all 
illustrated proof for functional vmiRNAs within the HIV-1 RNA genome, other 
groups have found contradictory results and failed to detect vmiRNA 
expression post-HIV-1 infection. More recently, a study utilized sensitive 
deep sequencing technology and found that HIV-1 does not seem to express 
any functional vmiRNA in infected cell lines, PBMCs, and primary 
macrophages (Whisnant et al., 2013).  
 
1.9.3. MiRNA Profiles in HIV-1-Infected Patient Cohorts 
One of the first reports on profiling miRNA expression was published by 
Houzet et al in HIV-1 seropositive individuals (Houzet L, 2008). They 
grouped the patients into four categories based on differential CD4+ T cell 
counts and viral load and compared miRNA expression profiles in PBMCs. 
They explored that, of the 63 miRNAs that were commonly changed, 4 
miRNAs were up-regulated and 59 were down-regulated in all seropositive 
individuals including miR-150, miR-191, miR-223, miR-16 and miR-146b 
(Houzet L, 2008).  
Witwer et al characterized global miRNA expression profiles in PBMCs from 
HIV-1-infected viremic patients and Elite suppressors (ES), to determine if 
differential miRNA expression profiles in ES might shed light on their 
resistance to virus-induced disease progression (Witwer et al, 2012). ES 
also known as elite controllers (EC) are a group of HIV-1-infected patients 
that are able to preserve excessively low to undetectable viral loads in 
blood (50 copies/ml, below the limit of detection of commercial assays) 
without antiretroviral therapy (ART) for many years and generally do not 
show any clinical signs of disease progression (Blankson JN. 2010).  
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Noticeably, they were able to identify specific miRNAs that were uniquely 
expressed in PBMCs from ES when compared to viremic patients and 
uninfected controls. Furthermore, anti-HIV-1 miRNAs including miR-125b, 
miR-150 and miR-29 were down-regulated in both ES and viremic patients 
(Witwer et al, 2012) and, miR-155, which inhibits HIV-1 infection in 
macrophages, was reported to be significantly higher only in viremic 
patients as compared to ES or healthy controls (Swaminathan G, 2012). 
More recently Reynoso et al., identified 3 miRNAs, miR29b, miR-33a and 
miR-146a that are more expressed in plasma of ES than HIV chronic 
infected patients. Moreover, they discovered that, after an HIV-1 infection 
assay, the overexpression of miR-33a and miR-146a drastically reduce viral 
replication in infected PBMC. These results suggested that these miRNAs 
might be used in developing therapeutic strategies against HIV especially 
considering that miR-29b is known to target Nef and alterations in Nef 
functions have been associated with slower progression to AIDS (Reynoso 
et al., 2014).  
Human miR-29b has been previously described as one of the key 
components characterizing ES miRNA profile as well as the one of infected 
patients with low viral load. Gorrono˜ et al found that PBMC from ES 
showed increased levels of miR-29b but also others miRNAs like miR- 221, 
miR-27a, hsa-miR-27b compared to viremic patients. On the other hand, the 
expression of 19 miRNAs was significantly down regulated in ES. Out of 
these miRNAs, miR-146a and miR-155 are the most important as they play 
a central role in a wide spectrum of immune function (L. Egaña-Gorroño, et 
al 2014). In summary, the published works reveal a differential expressed 
miRNA profile in Elite Suppressors that is similar to non-infected individuals 
and differs from Viremic Patients.  
Long-term non-progressors (LTNP) are HIV-1 seropositive individuals that 
naturally control viremia, but in detectable low levels (10,000 copies of 
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RNA/ml of blood) without ART, have normal CD4+ T cell counts and do not 
show the typical disease progression of HIV-1-infected individuals 
(Poropatich K, Sullivan DJ. 211). Mechanisms underlying resistance to or 
efficient control of HIV-1 infection in LTNP and HESN cohorts have not 
been well characterized. To this end, MiRNA expression profile has been 
evaluated by Bignami et al. in CD4+ T cells from LTNP, naïve healthy and 
HESN individuals (Bignami et al. 2012). Twenty-three miRNAs were 
differentially expressed between HESN and naïve healthy individuals. For 
instance, resting CD4+ T cells from HESN had significantly lower levels of 
miR-28-5p, miR-125b and miR-223 while miR-155, was expressed at higher 
levels in LTNP than in HESN. Furthermore, miRNA biogenesis proteins 
such as Dicer and Drosha were significantly down-regulated in CD4+ T cells 
derived from HESN individuals (Bignami et al. 2012).  
Finally, other study argued against the conclusions of previous work 
reveling lower levels of previously characterized miRNAs (miR-125b, miR-
31, miR-146b and miR-29a) (Witwer and Clements JE. et al. 2012). The 
controversial results may in part relate to differences in the cell types 
studied or in the technology and/or approaches used to detect and confirm 
miRNA expression. Future studies will be crucial in resolving such 
controversy. 
 
1.9.4. Cholesterol metabolism and MiR-233 
Cholesterol is critical for membrane integrity, signal transduction, and in 
general cellular physiology. There is a close relationship between lipid 
metabolism and antiviral responses. Many viral pathogens indeed exploit 
cellular lipid metabolism to ensure a correct amount of cholesterol for the 
release of functional virions (Matsumiya et al., 2013). 
Cholesterol homeostasis is accomplished through a complex network of 
sensing and effector mechanisms (Espenshade PJ, 2007). Liver control the 
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plasma cholesterol levels since it is responsible for the production of 
lipoproteins and the removal of excess systemic cholesterol through reverse 
cholesterol transport, cholesterol uptake, and sterol biliary excretion (Cuchel 
M, et al. 2010) (Ishibashi S, et al. 1993). In particular, the production of the 
25-hidroxy cholesterol (25-HC), a natural oxysterol that is produced through 
a cholesterol-25 hydroxylase (CH25H)-mediated enzymatic reaction, lead to 
the activation of liver X receptor (LXR) family. This event cause to the 
activation of ATP-binding cassette A1 (ABCA1) that promotes the efflux of 
cholesterol excess’s from the cells. (Park K et al., 2010).The connection 
between virus and cholesterol has been widely established in the last few 
years. According to this observation, studies have provided evidence that 
activation of LXRs results in the inhibition of viruses replication, including 
HIV and HCV. Regulation of cholesterol metabolism is largely mediated 
through interdependent regulatory modules, and miRNAs have appeared as 
critical components of this network (Moore KJ, 2010).  
Many genes associated with lipid and cholesterol metabolism are regulated 
by MiR-223 (Vickers KC, et al. 2013). Moreover, it has been established that 
miR-223 transcription and its mature levels are sensitive to intracellular 
cholesterol changes. MiR-223 regulates cholesterol biosynthesis, uptake, 
and efflux, thus demonstrating as a critical posttranscriptional regulatory 
coordinator of cholesterol metabolism (Vickers KC, et al. 2014).  
HIV-1 infection can impair both in vitro and in vivo reverse cholesterol 
transport (Djuranovic S, 2012) (Leung AK, 2010). In in vitro HIV-1 infected 
macrophages, the virus inhibits cholesterol efflux by Nef-mediated down-
regulation of adenosine triphosphate–binding cassette transporter A1 
(ABCA1) (Mujawar Z, 2006). ABCA1, also known as cholesterol efflux 
regulatory protein, is a protein encoded by the gene ABCA1 and is a major 
regulator of cellular cholesterol and phospholipid homeostasis as well as 
high-density lipoprotein (HDL) metabolism. It has been illustrated that 
ABCA1 mRNA and protein levels are significantly elevated with miR-223 
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overexpression (Vickers KC, et al. 2014) and the mechanism of action was 
shown to be indirect. Sp1 is a known transcriptional activator of ABCA1 while 
Sp3 is an antagonist of Sp1. Both mRNAs harbor putative miR-223 target 
sites, but only Sp3 mRNA levels were reduced by miR-223 overexpression, 
and in luciferase reporter assays, the putative target site was confirmed as 
functional. Thus, the proposed scenario is that the reduction in Sp3 by miR-
223 allows Sp1 greater positive sway over the ABCA1 promoter, with more 
efflux-promoting ABCA1 protein resulting. Consistent with this scenario was 
that when Sp3 itself was knocked down by siRNA, there was significant 
upregulation of ABCA1 gene expression, and with miR-223 overexpression, 
Sp3 nuclear binding activity decreased (Vickers KC, et al. 2014). In HIV-1 
infected cells, HIV induces a switch of cholesterol trafficking from 
physiological efflux to virus-controlled transport, thus reducing the ability of a 
cell to export excessive cholesterol. 
                                   
 
Figure 1.9. Schematic of miR-223 targets and regulatory modules associated with 
cholesterol metabolism. Cholesterol biosynthesis intermediates: a, acetoacetyl-CoA; b, β-
hydroxy-β-methylglutaryl-CoA; c, 4,4-dimethylcholesta-8(9),24-dien-3β-ol; and d, 4-
methyl,4-carboxycholesta-8(9)24-dien-3β-ol. (Vickers KC, et al., PNAS 2014). 
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1.9.5. Extracellular and Circulating miRNA 
Several studies have investigated the association of host cellular miRNAs in 
HIV-1 replication however; our knowledge of extra cellular and circulating 
miRNAs is limited. In 2008, miRNAs were detected in blood including 
plasma, platelets, erythrocytes, and nucleated blood cells. Plasma miRNAs 
were found to be surprisingly stable even under conditions as severe as 
boiling, low or high pH, long-time storage at room temperature, and multiple 
freeze-thaw cycles (Mitchell PS, 2008) (Lawrie CH, 2008) (Chen X, 2008). 
Recent studies have shown that to prevent their degradation, miRNAs can 
be packaged in microparticles (exosomes, microvesicles, and apoptotic 
bodies) (Zernecke A, 2009) (Valadi H, 2007) or associated with RNA-binding 
proteins (Argonaute2 [Ago2]) (Arroyo JD, 2011) or lipoprotein complexes 
(high-density lipoprotein [HDL]) (Vickers KC, 2011) (Figure 1.10).  
The presence of miRNAs in microparticles has also led to suggest that 
miRNAs are selectively targeted for secretion in one cell and taken up by a 
distant, target cell, possibly to regulate gene expression (Zernecke A, 2009). 
1.9.5.1. Plasma miRNAs in Microparticles 
Plasma RNA is protected from degradation by its inclusion in protein or lipid 
vesicles (El-Hefnawy T, 2004) which are known as exosomes, microvesicles 
(MVs), or apoptotic bodies depending on their size and mode of release from 
cells (Kosaka N, 2010) (Figure 1.10). 
Valadi et al found that some miRNAs were at approximately higher levels in   
exosomes than in their donor cells, which suggests an active mechanism by 
which selected miRNAs are promoted toward exosomes (Valadi H, 2007). In 
fact it has been confirmed that cells can indeed select some miRNAs for 
cellular release while others are retained (Pegati et al, 2010). 
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Figure 1.10. Cellular release mechanisms and extracellular transportation systems of 
miRNAs. In the nucleus, miRNAs are transcribed from DNA. A precursor hairpin miRNA 
(pre-miRNA) is formed after cleavage by the RNase III enzyme Drosha. After being 
transported into the cytoplasm, the pre-miRNA can be further cleaved into 19- to 23-
nucleotide mature miRNA duplexes. One strand of the miRNA duplex can be loaded into 
the RNA-induced silencing complex (RISC), where it can guide the RISC to specific mRNA 
targets to prevent translation of the mRNA into protein (1). The other strand may be 
degraded or released from the cell through export mechanisms described below. In the 
cytoplasm, pre-miRNAs can also be incorporated into small vesicles called exosomes, 
which originate from the endosome and are released from cells when multivesicular bodies 
(MVB) fuse with the plasma membrane (2). Cytoplasmic miRNAs (pre-miRNA or mature 
miRNA) can also be released by microvesicles, which are released from the cell through 
blebbing of the plasma membrane (3). MiRNAs are also found in circulation in 
microparticle-free form. These miRNAs can be associated with high-density lipoproteins or 
bound to RNA-binding proteins such as Ago2. It is not known how these miRNA-protein 
complexes are released from the cell. These miRNAs may be released passively, as by-
products of dead cells, or actively, in a miRNA-specific manner, through interaction with 
specific membrane channels or proteins (4). Although pre-miRNAs have been detected in 
exosomes and microvesicles, and mature miRNAs have been found in complex with Ago28 
and HDL, the exact proportion of mature and pre-miRNAs in the different extracellular 
compartments is not known (Creemers et al, Circ. Res, 2012). 
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1.9.5.2. MiRNAs Associated With Protein Complexes 
Recent studies showed that the majority of miRNAs are not found inside 
vesicle but rather are bound to RNA-binding proteins. Arroyo et al reported 
that almost up to 90% of miRNAs in circulation are present in a non–
membrane-bound form, whereas the minority of circulating miRNAs is 
vesicle-associated (Arroyo JD, 2011) (Figure 1.10).  
Protein K digestion of plasma specifically destabilizes these non–vesicle-
associated miRNAs, which demonstrates the existence of a miRNA-protein 
complex as a mechanism for their stability in the RNase-rich circulation. 
Further characterization indicated that a considerable portion of circulating 
miRNAs were associated with Ago2, the key intracellular effector protein of 
miRNA-mediated RNA silencing (Arroyo JD, 2011). Although, the exact 
mechanism is not clear, it has been proposed that the Ago2-miRNA 
complexes are passively released by death or apoptotic cells and remain in 
the extracellular space because of the high stability of the Ago2 protein. It is 
also possible that cell membrane–associated channels or receptors exist 
that allow for the specific release of these Ago2-miRNA complexes 
(Creemers et al, 2012). 
1.9.5.3. Circulating miRNAs Associated With HDL 
Recently, Vickers et al showed that endo-genous miRNA can be transported 
by high-density lipoprotein (HDL) (Vickers KC, 2011). They have an average 
size of 8 to 12 nm and are smaller than exosomes. Furthermore, HDL 
contains lipids, such as phosphatidylcholine which form stable ternary 
complexes with nucleic acids (Janas T and Yarus M. 2006). The mechanism 
of loading miRNAs into HDL is not known exactly; however, biophysical 
studies propose that HDL simply binds to extracellular plasma miRNAs 
through divalent cation bridging (Vickers KC, 2011).  
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1.9.5.4. MiRNAs in Cell-to-Cell Communication 
Zhang et al reported that miR-150 can be packed into MVs by human blood 
cells and directly delivered to cultured endothelial cells, reducing c-Myb 
protein levels, a validated target gene of miR-150 in target cells (Zhang Y, 
2010). Likewise, HDL from patients with hypercholesterolemia increased 
levels of miR-105, whereas HDL from HCs had no effect. HDL from familiar 
hypercholesterolemia patients induced significant gene expression changes 
in hepatocytes. This study provides evidence that HDL can deliver miRNAs 
to cells and alter gene expression (Vickers KC, 2011). These researches 
demonstrate that secreted miRNAs can be delivered effectively to cultured 
cells, where they can function as endogenous miRNAs.  
1.9.5.5. Circulating miRNAs as Biomarkers 
Mitchell et al. used a mouse prostate cancer model to study the presence of 
tumor- derived circulating miRNAs in plasma and found a strong correlation 
between miRNAs obtained from plasma and serum. Moreover, they were 
able to distinguish healthy subjects from patients with prostate cancer by 
measuring miR-141 level in serum (Mitchell PS, 2008). In the other study, 
the up-regulation of plasma miRNAs was detected in acute phase of HIV-1 
infected subjects and was associated with the progression of central nervous 
system disease (Witwer KW, 2011). Remarkably, MiRNAs appear as 
encouraging biomarkers to develop new miRNA- based therapies and 
diagnostic tools (Edwards JK. 2010).  
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The variability in susceptibility to HIV infection has been intensively studied 
and was found to correlate with a variety of viral, genetic, immunological and 
socio-behavioral variables which influence host cellular gene expression 
leading to increased antiviral activity (Clerici M et al. 1992).  
MicroRNAs are small 20-24nt non-coding RNAs that modulate gene 
translation of mRNAs by binding to complementary sequences in the 3'UTR 
of target transcripts. MicroRNAs are known to play essential functions in 
cellular differentiation, proliferation and apoptosis, and are also involved in 
human diseases, the modulation of innate and adaptive immunity, and host-
virus interaction (Bartel DP, 2004) (Zhao Y, 2007).  In particular, several 
studies examined the effects of HIV infection on miRNAs expression. 
MiRNAs have been shown to directly and indirectly modulate HIV 
replication via their interaction with cellular genes that influence such 
replication. Actually, 5 cellular miRNAs (miR-28, miR-125b, miR-150, miR-
223and miR-382) were shown to target the 3' LTR region of the HIV 
genome, thus contributing to the maintenance of latency in resting CD4+ T 
cells and monocytes (Huang et al, 2007). Despite several studies 
characterized the role played by different cellular miRNAs in HIV-1 infection 
in ex vivo and in vitro studies, only a limited number of reports have tried to 
analyze global miRNA profile in HESN and HIV-1-infected patients. 
Moreover, to our knowledge plasma miRNA profile of HESN cohorts in 
comparison to HIV-1 infected and HCs has not been investigated so far. 
Since a deeper understanding of miRNA profile in HESN individuals could 
open a new window to explore the mechanism behind the secret of natural 
resistance to the HIV-1 virus in HESN subjects, we profiled the expression 
of 84 miRNAs with a known antiviral and/or immunological activity in PBMC, 
monocytes, macrophages, plasma and supernatants of HIV-infected cells 
from a well-characterized Italian HESN cohort.  
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3.1. Sample Collection 
3.1.1. Sample population 
Blood samples were collected from 30 HESN and 30 HIV-1 positive 
individuals who are part of a serodiscordant cohort of heterosexual couples 
recruited at the S. Maria Annunziata Hospital in Florence, Italy followed since 
1997 (Mazzoli, 1997). Thirty age-matched HCs, without known risk factor for 
HIV infection, were also included in the study. The whole groups are Italian 
of Caucasian origin. Inclusion criteria for HESN was a history of multiple 
unprotected sexual episodes for more than 4 years at the time of the 
enrolment, with at least 3 episodes of at-risk intercourse within 4 months 
prior to study entry, and an average of 30 (range, 18 to >100) reported 
unprotected sexual contacts per year. All individuals (HESN and HIV-1 
infected) have been longitudinally followed for >4 years before the study by 
the Department of Obstetrics and Gynecology of the S. M. Annunziata 
Hospital.; which allowed us to exclude HESN and HIV-1 infected patients 
with sexually transmitted diseases or other reported pathologies during the 
time of study. The range of CD4 cell counts in HIV-1 infected patients was 
71-927 cells/ml, and viral loads were <50- >750,000 copies/ml. All the 
patients were receiving antiretroviral therapy (ART) at the time of the study. 
Written and informed consent was obtained from all subjects.  
 
3.1.2. Isolation of PBMC 
Peripheral blood mononuclear cells (PBMCs) were separated by whole 
blood on lymphocyte separation medium (Lympholyte-H, Cederlane 
Laboratories, Burlington, NC, USA). Briefly, whole blood was centrifuged for 
25 minutes at 2300 RPM, without brake, on a Ficoll discontinuous density 
gradient.  
After the centrifugation step, the blood sample was separated showing the 
following layers from top to bottom plasma and platelets, the PBMCs band 
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situated at plasma/Ficoll interface, Ficoll and red blood cells, covered by a 
granulocyte layer.  
The PBMCs layer were carefully removed from the tube and transferred to a 
new conical tube. The PBMCs were then washed with phosphate buffered 
saline (PBS) and cell number and cellular vitality were determined. 
 
3.1.3. Cell count 
The number and viability of the cell were determined by automated cell 
counter ADAM-MC (Digital Bio, NanoEnTek Inc, Corea). ADAM-MC 
automatic cell counter measures total cell numbers and viabilities by cutting 
edge detection technologies. Two sensitive fluorescence dye staining 
solutions, AccuStain Solution T (Propidium Iodide/lysis solution) and 
AccuStain Solution N (Propidium IodideI/PBS) are used in ADAM instead of 
tryphan blue staining which can lead to inaccurate data. AccuStain Solution 
T allows plasma membrane disruption and nucleus staining for 
measurement of total cell concentration. AccuStain Solution N allows 
staining of non-viable cells, thus leaving viable cells completely intact. A 532 
nm optic laser is automatically focused onto the cell solution inserted into a 
disposable microchip and cell analysis is made by a CCD detection 
technology. 
 
3.1.4. Monocyte isolation and Macrophages differentiation 
In order to calculate the percentage of monocyte in basal PBMC, 250,000 
cells were resuspended in PBS, and stained for surface antibodies: 
CD36FICT, CD4PC5, CD14PECY7 (Beckman-coulter, Fullerton, CA). After 
15 minutes cells were washed and fixed in 1% paraformaldehyde in PBS. 
After determining the percentage of monocyte at flow cytometer, 500,000 
monocyte/well were resuspended in RPMI 1640, seeded in a 12 wells 
monocyte attachment plate and incubated for 1 hour at 37°C with 5% CO2. 
Non-attached cells were removed by vigorously swirling the medium in the 
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well and aspirating the non-attached cells. One well for each subject was 
used for basal monocyte analysis and RNA was immediately extracted as 
described below (section 3.4.1).  
Furthermore, two wells for each HESN and HC subject were used for 
macrophages differentiation. In this step, after washing the wells with PBS, 
cells were cultured in RPMI 1640 containing 20% FBS and 100ng/ml of 
macrophages colony-stimulating factor (MCSF) at 37°C plus 5% CO2 for 5 
days. 
3.2. In Vitro HIV-1 Infection 
3.2.1 HIV-1 strains  
The R5 tropic HIV-1BaL (contributed by Drs. S. Gartner, M. Popovic and R. 
Gallo, courtesy of the National Institutes of Health AIDS Research and 
Reference Reagent Program) was used to perform In-vitro HIV-1 infection. 
The virus was provided through the EU programme EVA center for AIDS 
Reagents (The National Institute for Biological Standards and Control 
NIBSC, Potter Bars, UK). 
 
3.2.2. HIV-1 infection of PBMC 
Four x106 PBMCs isolated from HESN and HC were cultured in RPMI 1640 
containing FBS (20%), with or without 0.5ng/1x106 cells HIV-1Ba-L virus and 
incubated for 24 hours at 37°C and 5% CO2. Cells were then washed and 
resuspended in medium containing IL-2 (15ng/ml)(R&D systems, 
Minneapolis, Minnesota, USA) and PHA (1µg/ml)(Sigma–Aldrich, Saint 
Louis, Missouri, USA). Two days later cells were washed, resuspended in 
complete medium with IL-2, plated in 24-well tissue culture plates and 
incubated at 37°C and 5% CO2. One and 7 days post-infection 1x106 PBMC 
were analyzed for miRNA and gene expression while p24 antigen ELISA 
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was performed on 7-days post infection supernatants. MiRNA expression 
was analyzed on 7-days post infection supernatants as well. 
 
3.2.3. HIV infection assay of monocyte derived- macrophages (MDM) 
Following PBMCs isolation, monocytes were seeded in a 12 wells monocyte 
attachment plate for macrophages differentiation according to section 3.1.5.  
After differentiation assessment, macrophages from HESN and HC subjects 
were cultured in RPMI 1640 containing 20% FBS and 5ng/5 x105 cells HIV-
1Ba-L and incubated for 3 h at 37°C and 5% CO2. The attached macrophages 
were washed with PBS and cultured in complete medium containing 20% 
FBS for 9 days. Half of the medium was changed 3 and 5 days post 
infection. Nine days post infection supernatant was collected for p24 antigen 
ELISA while the attached macrophages were lysed with RNAZOL to extract 
RNA as described below (section 3.4.1). 
3.3. ELISA Assay 
3.3.1. P24 ELISA 
HIV-1 p24 Elisa assay kits (XpressBio, Frederick, MD, USA) were used to 
measure viral p24 on 7-days post infection PBMC and 9- days post infection 
MDM supernatant according to the manufacturer’s protocol.  
Microtitration wells were pre-coated with murine high specificity and affinity 
anti-HIV-1 P24 capture antibody. Five serial dilution (1:50 dilution) were 
prepared from a positive control to generate a linear standard curve. 
Controls and specimens were seeded together with a lyses buffer and 
incubated at 37°C for 60 minutes. All controls and samples were tested in 
duplicate. 
After washing the plate with a wash buffer (Tris buffered saline containing 
0.05% Tween 20) a detector antibody (anti-HIV p24 conjugated to biotin) 
was added into each well and incubated at 37°C for 60 minutes. 
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Subsequently, Streptavidin HRP conjugate (Streptavidin conjugated to 
horseradish peroxidase enzyme containing 0.01% Bromonitrodioxane) was 
added into wells and incubated for 30 minutes at room temperature (18-
25°C). Substrate solution (Tetramethlbenzidine) was added into the plate 
and incubated at dark and room temperature (18-25°C) for 30 minutes. 
Reaction was stopped by adding a stop solution (1 N H2SO4) to all wells.  
Plates were immediately read at 450 nm, using the IMark microplate reader 
equipped with Microplate Manager® 6 software (both from Biorad, Hercules, 
CA, USA). The absorbance of each microplate well was calibrated against 
the absorbance of an HIV-1 p24 antigen standard curve. Samples with 
absorbance values equal to or greater than the cutoff factor were considered 
initially reactive, but were retested in duplicate to determine whether the 
reactivity is reproducible. 
3.4. Total RNA extraction and miRNA isolation 
3.4.1. Total RNA extraction 
Total RNA was extracted from unstimulated, HIV-1 infected PBMC, CD4+ T 
cells, Monocyte and Monocyte- derived macrophages by using the acid 
guanidium thiocyanate-phenol- chloroform method. Cells were lysed by 
RNAzol B reagent (Duotech, Milan, Italy), a monophase solution containing 
phenol and guanidine thiocyanate, and later chloroform (20% of initial 
volume of RNAzol B) was added to separate the lysate into aqueous and 
organic phase. After centrifuging the samples (at 12,000g 15 minutes at 4°C) 
DNA and proteins were separated from the aqueous phase containing RNA. 
Total RNA was obtained from the aqueous phase by the isopropanol 
precipitation and washing with 75% ethanol and dissolved in RNase-free 
water (RQ1 DNase; Promega, Madison, WI, USA). The quality of RNA was 
tested using Nanodrop Spectrophotometer and only RNAs with high quality 
were used for further analysis. 
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3.4.2. Preparation of miRNAeasy Serum/Plasma Spike-In Control 
For quality control and to monitor the extraction efficiency of miRNA, 3.5µl 
(1.6X108 copies/µl) of synthetic cel-miRNA-39 (Qiagen, Venlo, Limburg, 
Netherlands) was spiked-into plasma and supernatant samples. The 
miRNAeasy Serum/Plasma Spike-In Control is a C. elegans miR-39 miRNA 
mimic and reconstitute by adding RNase-free water, resulting in a 2x1010 
copies/µl stock. 
 
3.4.3. MiRNA extraction from Plasma and cell culture medium 
MicroRNAs were isolated from 600µl of HESN, HIV+ and HC plasma sample 
and 300 µl supernatants of HIV-infected PBMCs by NucleoSpinMiRNA 
Plasma Kit (MACHEREY-NAGEL, Düren, Germany) according to the 
manufacturer’s protocol. Each sample was incubated with MLP buffer 
(Guanidiniumthiocyanate) at room temperature (RT) for 3min. Protein 
precipitation Buffer (MPP) and cel-miRNA-39 (Qiagen, Venlo, Limburg, 
Netherlands) (MPP) plus synthetic cel-miRNA-39 (Qiagen, Venlo, The 
Netherlands), for quality control and to monitor the extraction efficiency, were 
added to each sample. After centrifugation at 11,000 x g for 3min, the 
supernatant was collected and transferred to a new tube containing 
isopropanol. The total mixture was loaded to the NucleoSpinMiRNA column 
and after centrifuge for 30 s at 11,000 x g we discard the flow-through. The 
column was washed 3 times by adding wash buffer provided by kit (buffer 
MW1 and MW2). MicroRNAs were then eluted in 25µl of standard elution 
buffer and stored at -80˚C for further analysis. 
3.5. miScript Reverse transcription II RT  
One microgram of total RNA was reverse transcribed into first-strand cDNA 
in a 20µl final volume using miScript II RT Kit (Qiagen, Venlo, Limburg, 
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Netherlands) according to the manufacturer’s protocol. Each reaction 
contained: 10x miScript Nucleic mix, RNase free water, miScript reverse 
transcriptase mix and 5x miScript HiSpec buffer. The reverse transcription 
master mix was added to the RNA template and incubated for 60 minutes at 
37ºC; later the sample was incubated at 95ºC for 5 minutes to inactivate 
miScript reverse transcriptase. The reaction was diluted by adding 200µl 
RNase free water provided by kit and stored at -20ºC for further analysis.  
3.6. miScript PCR Array analysis 
Expression level of 84 miRNAs with antiviral and/or immunological function 
was evaluated in unstimulated PBMC and plasma samples using a miRNA 
PCR Array (MIHS-111Z) (Qiagen, Venlo, Limburg, Netherlands) (Table 3.1). 
Reactions were performed using a 2x QuantiTect SYBR Green PCR master 
mix (Qiagen, Venlo, Limburg, Netherlands).  
SYBR Green specifically binds double-stranded DNA by intercalating 
between base pairs, and fluoresces only when bound to DNA. Detection of 
the fluorescent signal occurs during the PCR cycle at the end of either the 
annealing or the extension step when the greatest amount of double-
stranded DNA product is present. By recording the amount of fluorescence 
emission at each cycle, the PCR reaction was monitored during exponential 
phase, where the first significant increase in the amount of PCR product 
correlates to the initial amount of target template. Reactions containing a 
greater amount of the initial template substrate generate a detectable 
amount of product (a detectable signal) earlier than reactions containing a 
smaller amount of template. Appearance of detectable fluorescence at an 
earlier cycle number indicates a greater amount of initial template substrate. 
The detectable amount of fluorescence, a signal significantly greater than 
background, is known as the threshold. The cycle during which a reaction 
emits that threshold level of fluorescence is known as the threshold cycle, 
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abbreviated Ct. A Ct value of 40 or higher means no amplification and this 
value was not included in the calculations.  
In summary, SYBR Green PCR master mix, 10x miScript universal primer, 
RNase-free water and template cDNA were mixed to prepare one reaction 
mix. Experiments were run on all of the subjects included in the study pooled 
into a unique HESN HC and HIV+ sample. Thus, the results represent the 
mean value of the different targets analyzed in HESN, HC and HIV+ 
subjects. The arrays were performed on CFX ConnectTM Real time PCR 
system (BIO RAD, Hercules, CA, USA) using the following running protocol: 
Initial activation step at 95°C for 15 minutes, 40 cycles at 94°C for 15 
seconds (denaturation) and 55°C for 30 seconds (annealing), followed by 1 
step at 70°C for 30 seconds (extension). Undetermined raw Ct values were 
set to 40. Expression profile was analyzed using the PCR Array Gene 
Expression Analysis Software (SABiosciences, Frederick, MD, USA). For 
each miRNA, Ct values were transformed into relative quantities using as 
normalization factor the arithmetical mean of the reference miRNAs available 
in the arrays (SNORD68, SNORD72, RNU6-2 for basal PBMC and miR-93 
and RNU6-2 for plasma samples). Controls were also included on each 
array for genomic DNA contamination, RNA quality, and general PCR 
performance. Fold regulation of ± 2.5 was considered as significant. 
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T‐Cell Differentiation   
Double Negative 
(CD4‐/CD8‐): 
let‐7d‐5p, let‐7e‐5p, miR‐126‐3p, miR‐128, miR‐146b‐5p, miR‐15a‐5p, miR‐17‐
5p, miR‐17‐3p, miR‐181c‐5p, miR‐191‐5p, miR‐9a‐3p, miR‐199a‐5p, miR‐20a‐5p, 
miR‐20b‐5p, miR‐221‐3p, miR‐222‐3p, miR‐223‐3p, miR‐28‐5p, miR‐29c‐3p, 
miR‐138‐5p, miR‐342‐3p, miR‐423‐5p, miR‐93‐5p, miR‐98‐5p. 
Double Positive 
(CD4+/CD8+): 
let‐7b‐5p, miR‐181a‐5p, miR‐181b‐5p, miR‐181d, miR‐19b‐3p.
CD4+ Naive:  miR‐132‐3p, miR‐146a‐5p, miR‐182‐5p, miR‐184, miR‐25‐3p, miR‐326, miR‐92a‐3p. 
CD8+ Naive: 
let‐7a‐5p, let‐7c, let‐7f‐5p, let‐7g‐5p, miR‐130b‐3p, miR‐139‐5p, miR‐142‐3p, 
miR‐150‐5p, miR‐155‐5p, miR‐15a‐3p, miR‐16‐5p, miR‐26a‐5p, miR‐26b‐5p, 
miR‐29b‐3p, miR‐30b‐5p, miR‐30c‐5p, miR‐30d‐5p. 
CD8+ Effector:  miR‐147a, miR‐148a‐3p, miR‐18a‐5p, miR‐27a‐3p, miR‐27b‐3p.
CD8+ Memory:  let‐7i‐5p, miR‐106b‐5p, miR‐142‐5p, miR‐15b‐5p, miR‐17‐5p, miR‐21‐5p, miR‐23a‐3p, miR‐23b‐3p, miR‐24‐3p, miR‐29a‐3p, miR‐31‐5p. 
B‐Cell Differentiation:   
Naive: 
let‐7a‐5p, let‐7b‐5p, let‐7d‐5p, let‐7g‐5p, let‐7i‐5p, miR‐101‐3p, miR‐132‐3p, 
miR‐142‐3p, miR‐142‐5p, miR‐150‐5p, miR‐181c‐5p, miR‐195‐5p, miR‐204‐5p, 
miR‐214‐3p, miR‐221‐3p, miR‐222‐3p, miR‐223‐3p, miR‐29b‐3p, miR‐30e‐5p, 
miR‐331‐3p, miR‐92a‐3p. 
Germinal Center: 
miR‐106b‐5p, miR‐130b‐3p, miR‐132‐3p, miR‐148a‐3p, miR‐15a‐5p, miR‐15b‐
5p, miR‐16‐5p, miR‐17‐5p, miR‐17‐3p, miR‐181a‐5p, miR‐181b‐5p, miR‐191‐5p, 
miR‐19a‐3p, miR‐19b‐3p, miR‐210, miR‐23b‐3p, miR‐25‐3p, miR‐28‐5p, miR‐
30d‐5p, miR‐93‐5p, 
Memory: 
miR‐100‐5p, miR‐125b‐5p, miR‐145‐5p, miR‐146a‐5p, miR‐155‐5p, miR‐21‐5p, 
miR‐23a‐3p, miR‐24‐3p, miR‐26a‐5p, miR‐26b‐5p, miR‐27a‐3p, miR‐27b‐3p, 
miR‐29a‐3p, miR‐29c‐3p, miR‐30b‐5p, miR‐30c‐5p, miR‐34a‐5p. 
Differentially 
Expressed in Tregs: 
miR‐100‐5p, miR‐125b‐5p, miR‐146a‐5p, miR‐181c‐5p, miR‐20b‐5p, miR‐21‐5p, 
miR‐31‐5p, miR‐335‐5p, miR‐365a‐3p, miR‐99a‐5p. 
T‐Cell Activation: 
let‐7e‐5p, let‐7i‐5p, miR‐106b‐5p, miR‐139‐5p, miR‐142‐5p, miR‐146a‐5p, miR‐
146b‐5p, miR‐155‐5p, miR‐15a‐5p, miR‐15a‐3p, miR‐181a‐5p, miR‐181c‐5p, 
miR‐195‐5p, miR‐20b‐5p, miR‐214‐3p, miR‐223‐3p, miR‐23a‐3p, miR‐23b‐3p, 
miR‐25‐3p, miR‐26a‐5p, miR‐26b‐5p, miR‐27a‐3p, miR‐27b‐3p, miR‐29a‐3p, 
miR‐29b‐3p, miR‐29c‐3p, miR‐30a‐5p, miR‐30b‐5p, miR‐30e‐5p, miR‐342‐3p, 
miR‐346, miR‐574‐3p, miR‐98‐5p 
Table 3.1 – Complete list of T-Cell & B-Cell Activation miScript miRNA PCR Array analyzed 
(SABiosciences) 
3.7. Individual miScript Real-Time PCR 
Target miRNAs showing marked differences between HESN, HC and HIV+ 
patients in both unstimulated PBMC and plasma were retested by RT-PCR 
on each individual sample (PBMC, plasma, supernatant, monocyte, MDM 
and CD4+ T cells). Samples were amplified using the miScript SYBR Green 
PCR Kit with the same running protocol used for array analyses.  
The primers (Qiagen, Venlo, Limburg, Netherlands) used were: hsa-miR-
15a-5p, hsa-miR-16-5p, hsa-miR-17-5p, hsa-miR-21-5p, hsa-miR-26a, has-
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miR-28-5p, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-29c-3p, hsa-miR-
34a-5p, hsa-miR-92a-3p, hsa-miR-125b-5p, hsa-miR-138-5p, hsa-miR-146a-
5p, hsa-miR-150-5p, hsa-miR-155-5p, hsa-miR-190b, hsa-miR-223-3p, hsa-
miR-326, hsa-miR-382-5p. Endogenous controls used to normalize the 
relative miRNA expression were: small RNA U6 for isolated cells (PBMC, 
monocyte, MDM and CD4+ T cells) and miR-425 and miR-93 for extracellular 
miRNA (plasma and supernatant samples) as used by others (Sung et al, 
2009) (Thapa, 2014) (Zhu W, 2009). Synthetic cel-miRNA-39 was also used 
as quality control of miRNA extraction for the measurement of extracellular 
miRNA (Thapa, 2014). Melting point or dissociation curve analysis was 
performed for amplicon identification for all miRNAs. 
Experiments were performed in duplicates for each sample; reverse 
transcriptase-negative controls were included in each batch of reactions. The 
fold changes in miRNAs were calculated by the equation 2-∆∆Ct as ratios 
between the target gene and the housekeeping miRNAs. 
3.8. cDNA synthesis and retrotranscription (RT) 
One microgram of RNA from unstimulated PBMCs was reverse transcribed 
into first-strand cDNA in a 20µl final volume containing 1 µM oligonucleotide, 
1 µM random hexanucleotide primers and 200 U Moloney murine leukemia 
virus reverse transcriptase (Promega). 
Total RNA was dissolved in RNase-free water, and purified from genomic 
DNA with TURBO DNAse (Applied Biosystems/Ambion, Austin, TX, USA), a 
genetically engineered form of bovine DNase I with greater catalytic 
efficiency than conventional DNase I at higher salt concentrations and lower 
DNA concentrations. One reaction mixture, containing 1µg of RNA, Turbo 
DNasi 1U and TURBO DNasi Buffer, was incubated at 37°C for 30 minutes. 
Then DNase inactivation reagent (Applied Biosystems/Ambion, Austin, TX, 
USA), was added to the mixture to inactivate the DNase, since it can bind 
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and remove the divalent cations from DNase. Subsequently, a reaction 
mixture  containing 1 µM random hexanucleotide primers, 1 µM oligo dT and 
the RNA was heated at 70°C for 5 minutes to melt secondary structure within 
the template. The mixture was immediately cooled on ice to prevent 
reforming secondary structures. Finally, dNTPs mix, 200U Moloney murine 
leukemia virus reverse transcriptase (M-MLV RT), 20U Recombinant RNasi 
inhibitor and M-MLV 5X reaction buffer were added to each sample 
(Promega, Fitchburg, WI, USA). The reaction mix were incubated at 42°C for 
60 minutes and then heated 5 minutes at 95°C to inactivate the RT mix. 
3.9. Real time PCR and gene expression analysis 
Real time PCR was performed for Dicer, Drosha, ABCA1 and GAPDH on 
CFX ConnectTM Real time PCR system (BIO RAD, Hercules, CA, USA) 
using a SYBR Green PCR mix (BIO RAD). Results were calculated by 2-∆∆Ct 
equation as ratios between the target and GAPDH as a housekeeping gene. 
Reactions were performed according to the following thermal profile: an 
initial 95°C for 15 minutes (denaturation) followed by 40 cycles of 15 sec at 
95°C (denaturation), 1 min at 60°C (annealing) and 20 seconds at 72°C 
(extension). Melting curve analysis was also performed for amplicon 
identification. Ct value of 40 or higher not included in the calculations. All the 
samples were analyzed in duplicate. The primers   are   summarized   in   
Table 3.2. 
 
GAPDH For Rev 
CGGATTTGGTCGTATTGGG 
GCTTCCCGTTCTCAGCCTTG 
DICER For Rev 
GGGGTGTGTGAAGGGGGATA 
ACAGCAAGGCAGGACCAAGC 
DROSHA For Rev 
CCTGCGTCTGCTGTTCGTCT 
GGCTGGGGTGTTTTGAGTGG 
ABCA1 For Rev 
CCCAAGATGACAAGTAACATGCTC 
GGAAGCGCTCCTGTTGCAG 
Table 3.2. List of primers used to assess the expression of DICER, DROSHA and ABCA1 
genes. GAPDH was used as an endogenous housekeeping gene. 
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3.10. Flow cytometric analysis 
Gallios flow cytometer (Beckman-Coulter, Miami, FL), supplied with a double 
15-mW argon ion laser operating at 456 and 488, was used to perform all 
the cytometric analyses. Data were analyzed using Kaluza software 
(Beckman Coulter). Monocyte percentage was checked by staining with the 
FITC- labelled anti-human CD14 monoclonal antibody (clone RMO52, 
Beckman Coulter). For each analysis, we acquired 20,000 events. Green 
fluorescence from FITC (FL1) was gathered through a 525-nm band-pass 
filter. Linear amplifiers were utilized to collect the data for forward and side 
scatter and logarithmic amplifiers for FL1.  
3.11. Statistical analysis 
The relative expression levels of miRNA and target gene were calculated 
using the comparative ∆∆Ct method as described previously. The fold 
changes were calculated by the equation 2-∆∆Ct. Data were analyzed using 
Student’s T or ANOVA test by GRAPHPAD PRISM version 5 (Graphpad 
software, La Jolla, Ca, USA), and p-values of 0.05 or less were considered 
to be significant. 
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4.1. Differential miRNA expression in unstimulated PBMC 
In order to verify if natural resistance to HIV-1 infection is associated with a 
specific miRNA profile we evaluate the expression of 84 miRNAs (Table 3.1) 
endowed with immunomodulant and/or antiviral properties. Therefore, a Real 
time PCR array was performed on unstimulated PBMC of 30 well 
characterized HESNs (Biasin 2010), 30 HIV-1 positive and 30 HC 
individuals. At first, we decided to examine PBMC miRNA expression rather 
than focusing on subsets of cells, since PBMCs include the major circulating 
targets of HIV infection and knowledge of overall expression is the logical 
first step towards characterizing cell subtype expression. Individual samples 
were grouped together in these initial assays to create 3 different pools and 
the expression level of miRNAs was evaluated using a miRNA PCR Array 
(MIHS-111Z). Array results were calculated relative to SNORD68, 
SNORD72, and RNU6-2 expression. 
Results showed that, whereas the expression of 50 miRNAs was 
comparable in the three groups, 1) 10 miRNAs mir-26b, mir-29b, mir-29c, 
mir-34, mir-146, mir-148a, mir-155, mir-195, mir-326 and mir-365b) were 
significantly increased in both HESN and HIV+ individuals compared to HC; 
2) 9 miRNAs (mir-9a, mir-17, mir-18a, mir-20b, mir-21, mir-106b, mir-126, 
mir-130b and mir-182) were upregulated and 3 miRNAs (mir-138, mir-150 
and mir-190) were down regulated only in HIV+ compared to HC; and 3) the 
expression of 12 miRNAs (mir-15a, mir-16, mir-26a, mir-28, mir-29a, mir-92, 
mir-99a, mir-125b, mir-128, mir-142, mir-223 and mir-423) was significantly 
augmented in HESN alone compared with HC (Figure 4.1A). 
4.2. Differential miRNA expression in plasma 
The plasma concentration of the same miRNAs was measured next in our 
samples, once again grouped into 3 pools. The expression level of miRNAs 
was evaluated using a miRNA PCR Array (MIHS-111Z) and results were 
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calculated relative to miR-93 and RNU6-2. Also in this case, whereas 53 
miRNAs did not show any different modulation between three groups, the 
concentration of 31 miRNAs distinguished them. Thus: 1) the concentration 
of 13 miRNAs (mir-23b, mir-28, mir-29a, mir-29b, mir-29c, mir-30c, mir-146, 
mir-150, mir-155, mir-190, mir-346, mir-326 and mir-382) was similarly 
increased in HESN and HIV-infected individuals compared to HC; 2) 6 
miRNAs (mir-16, mir-17, mir-34, mir-92, mir-210 and mir-31) were increased 
only in HIV+ patients compared to HC; and 3) 12 miRNAs (mir-15a, mir-21, 
mir-25, mir-26a, mir-98, mir-125b, mir-138, mir-139, mir-147a, mir-184, mir-
214 and mir-223) were augmented in plasma of HESN alone compared to 
HC (Figure 4.1B). 
4.3. Validation of miRNA expression in unstimulated PBMC by 
individual Real Time PCR 
To further confirm these results, the expression of the 20 miRNAs (miR-17, 
miR-21, miR-26, miR-28, miR-29a, miR-29b, miR-29c, miR-34a, miR-92, 
miR-125b, miR-133b, miR-138, miR-146, miR-149, miR-150, miR-155, miR-
190, miR-223, miR-326 and miR-382) that were augmented in unstimulated 
PBMC and/or in plasma of HESN and HIV-infected individuals was validated 
by individual real time PCR. Results were calculated relative to snRNA U6 
as an endogenous control to normalize miRNA expression and they are 
shown as fold change expression. Results obtained in unstimulated PBMC 
confirmed that all these miRNAs are differently expressed in HESN and HIV-
infected individuals compared to HC (Figure 4.2A and 4.2B), with statistically 
significant differences being observed in 5 cases (miR-29a, miR-138, miR-
150, miR-190, and miR-223) (Figure 4.2B). Notably, amongst these 5 
molecules 3 miRNAs (miR-138, miR-150 and miR-190) play a role in HIV-1 
latency: the expression of these 3 miRNAs was significantly reduced in HIV-
infected patients alone.  The expression of the 2 remaining miRNAs (miR-
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29a and miR-223) was significantly increased exclusively in HESN (p<0.01 
for all comparisons) (Figure 4.2B): these miRNAs are known to suppress 
HIV replication.  
4.4. Validation of miRNA in plasma by individual Real Time PCR 
Plasma concentration of the same 20 miRNAs was validated as well by 
individual real time PCR using miScript SYBR Green PCR Kit. MiRNA 
expression level was analyzed using miR-93 and miR-425 to normalize the 
relative miRNA. Also, since it is not possible to test the quality of MiRNA 
using Nanodrop Spectrophotometer, spiked-in Ce-miR-39-1 was used to 
monitor the extraction efficiency of obtained miRNA. Only miRNAs with the 
approximately same Ce-miR-39-1 Ct values were used for further analysis. 
Results confirmed that all the miRNA analyzed are differently expressed in 
the three groups (Figure 4.3A); furthermore, the concentration of 10 of these 
miRNAs (miR-28, miR-29a, miR-29b, miR-29c, miR125b, miR-146, miR-150, 
miR-155, miR-190 and miR-382) is increased in both HESN and HIV+ 
individuals compared to HC (Figure 4.3B), indicating the presence of a 
“retroviral exposure signature” that is shared between these two groups of 
individuals, and occurs even in the absence of a productive infection. 
Plasma expression of miR-138 and miR-223, however, was increased in 
HESN alone compared to either HIV patients (miR-138 and miR-223: 
p<0.03) or HC (miR-138: p<0.03; miR-223: p<0.0001) (Figure 4.3B). As the 
PCR normalizers used in the array and in the individual PCR are different, 
the replication of the results strengthens the key role played by these 
miRNAs in natural resistance to HIV-1 infection.  
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4.5. HIV-1 p24 and miRNA expression analyses following in vitro 
HIV infection of PBMC 
To verify if miRNA expression is altered following HIV-1 infection, the same 
20 miRNAs were analyzed in PBMCs from HESN and HC in vitro infected 
with R5 HIV virus. MiRNA expression was analyzed on PBMC at 7 days 
post-infection while p24 antigen was quantified on supernatants of in vitro 
HIV infected PBMCs. 
HIV-1 p24 ELISA confirmed that PBMC from HESN display a better control 
of HIV-1 infection, in fact HC individuals sustain significantly higher HIV-1Ba-L 
replication compared with that of HESN individuals (Figure 4.4A). No 
differences in miRNA expression were observed 1 day post infection in 
HESN compared to HC (data not shown). Seven days post infection; 
nevertheless, all the 20 analyzed miRNAs were down regulated to various 
extents in HESN compared to HC (Figure 4.4B); these differences reached 
statistical significance for miR-28 (p<0.006), miR-29a (p<0.04), miR-125b 
(p<0.05), miR-150 (p<0.02) and miR-223 (p<0.05) (Figure 4.4C). Our results 
suggest that following HIV-1 infection these miRNAs are released in the 
extracellular milieu where they could display a paracrine control over 
neighboring cells. 
4.6. Differential miRNA expression in supernatant from HIV-
infected PBMC 
To verify whether miRNAs are indeed released in the extracellular milieu by 
HIV-1 infected cells, the expression level of the 20 selected miRNAs that 
were down-regulated in in vitro HIV-infected PBMCs (see above) was 
analyzed next in the supernatant from the same PBMCs.  
Results showed that this was indeed the case as the expression level of all 
the analyzed miRNAs was higher 7-days post infection in supernatants of 
HESN compared to those of HC (Figure 5.5A). These differences reached 
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statistical significance for miR-28 (p<0.05), miR-29a (p<0.04), miR-125b 
(p<0.05), miR-150 (p<0.05) and miR-223 (p<0.05) (Figure 5.5B). 
4.7. Differential miRNA expression in isolated Monocytes 
We then decided to analyze miRNA profile in fractionated PBMC starting 
from basal monocyte. Ten miRNAs were analyzed in basal monocyte based 
on their role in HIV-1 infection in monocytes (Wang et al, 2009) (Sung et al, 
2009): miR-28, miR-29a, miR-29b, miR-125b, miR-150, miR-155, miR-190, 
miR-198, miR-223 and miR-382. Likewise to miRNA signature in basal 
PBMC, HESNs profile in monocytes clustered with HCs ones (Figure 4.6A); 
conversely HIV-1 infected patients showed a significant reduction in anti 
HIV-1 miRNA expression (miR-29a, miR-28, miR-125b and miR-150) 
suggesting that a decline in these miRNA increases susceptibility to HIV-1 
infection (Figure 4.6B).  However, the expression of miR-198 and miR-223 
was significantly augmented only in HESN subjects compared to both HIV-
1+ patients (p<0.01) and HC (p< 0.05) (Figure 4.6A). The other tested 
miRNAs showed the same trend and had higher miRNA expression in HESN 
individuals and HCs (Figure 4.6B). PCR results were calculated relative to 
snRNA U6 to normalize miRNA expression.  
4.8. HIV-1 p24 and miRNA expression analyses following in vitro 
HIV infection of MDM 
Macrophages derived from monocyte (MDM) from HESN and HC subjects 
were infected with HIV-1Ba-L virus and miRNA expression profile was 
evaluated 9-days post infection. HIV-1 p24 ELISA established that MDM 
from HESN are able to better cope with HIV-1 infection compared with HC 
ones (p<0.01) (Figure 4.7A). Furthermore, reduced susceptibility to HIV-1 
infection in HESN MDM was associated with higher expression of all our 
tested miRNAs compared to HCs (Figure 4.7B); these differences reached 
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statistical significance for miR-29a, miR-150, miR-155, miR-190, miR-198, 
miR-223 and miR-382. Thus strengthening the protective role exerted by 
these miRNAs in resistance to HIV-1 infection (Figure 4.7C). 
4.9. Analyses of ABCA1 expression level 
As Vickers et al. showed that the overexpression of miRNA-233 elevates 
ABCA1 mRNA and protein levels (Vickers KC, et al. 2014), we analyzed its 
expression in unstimulated PBMCs as well as in monocytes and HIV-
infected MDM isolated from all the individuals included in the study (Figure 
4.8). Interestingly, ABCA1 mRNA level was higher in both PBMC (Figure 4.8 
A) and monocytes (Figure 4.8 B) from HESN and HIV+ subjects compared 
with HC (PBMC: HESN vs HC p<0.001; HIV+ vs HC p<0.05. Monocytes: 
HESN vs HC p<0.05) showing the highest expression in HESN individuals 
(PBMC: HESN vs HIV+ p<0.01. Monocytes: HESN vs HIV p<0.05). 
Likewise, the expression of ABCA1 was significantly increased even in HIV-1 
infected MDM from HESN compared to HC ones (p<0.01). These results 
confirmed that in HESN subjects the up-regulation of miR-223 is 
accompanied by an increased expression of ABCA1 (Figure 4.8). 
4.10. Analysis of Dicer and Drosha expression level  
As increased expression levels of miRNAs could be secondary to higher 
levels of Dicer and Drosha, two essential enzymes in miRNA biogenesis, 
these enzymes were analyzed in unstimulated PBMCs of all of the subjects 
included in the study.  
However, our results did not show any appreciable difference in the 
expression level of Dicer and Drosha in PBMCs of HESN compared to HC 
and HIV+ individuals (Figure 4.9). 
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Figure 4.1. Vann diagram of miRNA profile in unstimulated PBMC (A) and plasma samples 
(B) of HESN and HIV+ individuals. The miRNAs differentially expressed in HESN and HIV+ 
samples compared to HC are shown in two overlapping circles. (A) Results were calculated 
relative to SNORD68, SNORD72, RNU6-2 expression. (B) Results were calculated relative to 
Ce_miR-39_1, miR-93 and RNU6-2. Fold regulation of ±2.5 was considered as significant. 
The miRNAs with fold-regulation values less than -2.5 (downregulation) are indicated in bold. 
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Figure 4.2. MiRNA expression analysis in unstimulated PBMC by individual real time PCR. 
Analyses were performed on unstimulated PBMCs of 30 HC (white bars), 30 HESN (black 
bars) and 30 HIV+ (gray bars) individuals. Results were calculated relative to snRNA U6 as 
an endogenous control to normalize miRNA expression. Results confirmed that all these 
miRNAs are differently expressed in the 3 groups (A), with statistically significant differences 
being observed for 5 miRNAs (B). Values are expressed as mean ± SE. Significance is 
indicated as follows: * = p˂0.05. 
 
 
 94 
 
 
 
Figure 4.3. MiRNA expression analysis in plasma samples by individual real time PCR. 
Plasma samples were collected from 30 HC (white bars), 30 HESN (black bars) and 30 HIV+ 
(gray bars) individuals. MiRNA expression level was analyzed using miR-93, miR-425 and 
Ce-miR-39-1 to normalize the relative miRNA and to monitor the miRNA extraction efficiency. 
(A) Results confirmed that all the miRNA analyzed are differently expressed in the three 
groups; with statistically significant differences being observed for 12 miRNAs (B). Values are 
expressed as mean ± SE. Significance is indicated as follows: * = p˂0.05, **= p<0.01, ***= 
p<0.001. 
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Figure 4.4. PBMC from 30 HESN (black bar) and 30 HC (white bar) were in vitro infected with 
HIV-1Ba-L for 7 days. (A) P24 levels were measured from HIV-1BaL-Infected cells. Seven days 
post infection; all the 20 analyzed miRNAs were down regulated to various extents in HESN 
compared to HC (B); these differences reached statistical significance for 5 miRNAs (C). RNA 
U6 was used as endogenous control to normalize the relative miRNA expression. Results are 
shown as mean ± SE. Significance is indicated as follows: * = p˂0.05; **= p<0.01. 
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Figure 4.5. PBMCs isolated from 30 HC (white bars) and 30 HESN (black bars) individuals 
were infected with HIV-1Ba-L and miRNA expression level was analyzed on 7 day post 
infection supernatant. Expression level of all the analyzed miRNAs was higher 7-days post 
infection in supernatants of HESN compared to those of HC (A). These differences reached 
statistical significance for 5 miRNAs (B). MiR-93, miR-425 and Ce-miR-39-1 were used to 
normalize the relative miRNA and to monitor the miRNA extraction efficiency. Values are 
mean ± SE. Significance is indicated as follows:  * = p˂0.05. 
 97 
 
 
 
Figure.4.6. Monocytes were isolated from 30 HC (white bars), 30 HESN (black bars) and 30 
HIV+ (gray bars) individuals. MiRNA expression was calculated relative to snRNA U6 as an 
endogenous control to normalize miRNA expression. (A) HESNs profile in monocytes 
clustered with HCs ones; (B) statistically significant differences were observed for 6 miRNAs. 
Values are shown as mean ± SE. Significance is indicated as follows: * = p˂0.05. 
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Figure 4.7. MDMs of 30 HC (white bars) and 30 HESN (black bars) individuals were infected 
with HIV-1Ba-L. (A) P24 levels measured from HIV-1BaL-Infected cells. (B) Reduced 
susceptibility to HIV-1 infection in HESN MDM was associated with higher expression of all 
tested miRNAs compared to HCs; (C) these differences reached statistical significance for 6 
miRNA. RNA U6 was used as endogenous controls to normalize the relative miRNA 
expression. Results are shown as mean ± SE. Significance is indicated as follows: * = p˂0.05; 
**= p<0.01. 
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Figure 4.8. Cells were isolated from 30 HC (white bars), 30 HESN (black bars) and 30 HIV+ 
(gray bars) individuals. Results were calculated relative to GAPDH expression and they are 
shown as fold change expression. ABCA1 mRNA expression in basal PBMC(A) monocytes 
(B) and MDM (C) by real time PCR. Values are mean ± SE. Significance is indicated as 
follows: * = p˂0.05; **= p<0.01. 
 
 
 
Figure 4.9. Dicer and Drosha mRNA expression in basal PBMC by real time PCR. Basal 
PBMCs were isolated from 30 HC (white bars), 30 HESN (black bars) and 30 HIV+ (gray 
bars) individuals. Results were calculated relative to GAPDH expression and they are shown 
as fold change expression. Values are mean ± SE. 
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DISCUSSION & CONCLUSIONS 
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Eighty-four miRNAs which are mainly expressed by lympho-monocytes and 
involved in the regulation of immune responses and/or in host virus 
interaction (Bartel, 2009) (Guo, 2010) were analyzed to verify whether a 
particular miRNA profile could be identified in HESN; results were validated 
by analyses on 20 of these miRNAs by individual real time PCR. The 
decision to study miRNA profile in PBMC was based on their accessibility 
and on the fact that PBMC include the major circulating targets of HIV-1 
infection, and therefore represent the logical first step towards characterizing 
cell subtype expression. Findings herein show that a number of miRNAs is 
upregulated both in HESN and HIV-infected individuals, indicating that 
exposure to HIV impairs the miRNA profile independently of the 
establishment of overt infection. Additional results indicated that the 
expression of miR-29a and miR-223 was significantly augmented in HESN 
alone. Because these two miRNAs are known to hamper HIV replication the 
detection of their up-regulation in both plasma and cell culture medium from 
HIV-1 infected PBMC of HESN suggests a protective role for these 
molecules in resistance to HIV-1 infection. Finally, results showing that the 
expression level of Dicer and Drosha, two enzymes playing essential roles in 
miRNA biogenesis, was comparable in HIV-infected individuals, HESN and 
HC suggest that exposure to HIV changes miRNAs profiles through 
mechanisms that are independent of Dicer and Drosha. Yet, in the light of 
recent acquisition suggesting that Drosha protein level and nuclear 
localization can be altered by molecular mechanisms such as ubiquitination, 
acetylation (Tang X et al, 2013) and phosphorylation (Tang X et al, 2010), 
without affecting mRNA levels, we cannot rule out that differences in miRNA 
expression observed in our cohort are dependent on these mechanisms. 
Further analyses are needed to elucidate this aspect”.  
MicroRNA-29a has been shown to play a crucial role in thwarting HIV 
replication since it is able to bind both the 3’ UTR sequence and the HIV-1 
encoded protein Nef, hence preventing viral replication (Ahluwalia JK et al, 
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2008). Recent studies have also shown that reduced expression levels of 
miR-29a have been seen in HIV-1 infected patients and have been 
associated with the presence of a secondary structure within the miR-29a 
binding region in HIV-1 LTR (Sun G et al, 2012). MiR-223, on the other 
hand, is part of a selected group of cellular miRNAs known to play an active 
role in modulating the ability of HIV-1 to infect resting CD4+ T lymphocytes 
(Huang J et al, 2007). This effect was demonstrated to depend on the ability 
of miR-223 to bind the 3’ UTR of viral mRNA through sequence 
complementary. Notably, activation of resting CD4+ T cells, a process 
known to trigger HIV replication and to enhance HIV-1 susceptibility is 
associated with the down-regulation of this miRNA. Two other independent 
studies confirmed miR-223 to be down regulated upon differentiation from 
monocyte to macrophages, thus shedding light on the mechanisms 
associated with the productive HIV-1 infection, taking place in monocytes 
(Wang X et al, 2009)(Sisk JM et al, 2012). Finally, recent results showed that 
miR-223 indirectly modulates cyclin T1 expression, resulting in lower HIV-1 
replication (Chiang K et al, 2012), and plays a critical role in systemic 
cholesterol regulation by coordinated post-transcriptional control of multiple 
genes in cholesterol metabolism (Vickers KC et al, 2014).  
In particular, it has been illustrated that adenosine triphosphate–binding 
cassette transporter A1 (ABCA1) mRNA and protein levels are significantly 
elevated following miR-223 overexpression (Vickers KC, et al. 2014). 
Furthermore, in in vitro HIV-1 infected macrophages, it has been 
demonstrated that the virus inhibits cholesterol efflux by Nef-mediated down-
regulation of ABCA1 (Mujawar Z, 2006).These data are in line with the 
observation that in our HESN samples miR-223 overexpression is 
associated with increases in ABCA1 mRNA compared to HCs and HIV+ 
samples in PBMC as well as monocytes and MDM. Further analyses are 
needed to prove a cause-effect relation between these two variables but 
these preliminary results let us to speculate that higher Mir-223 levels could 
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contribute to ABCA-1 increase which in turn could regulate the intracellular 
cholesterol metabolism, essential for the correct assembly and release of 
functional virions. 
Notably, our results are in conflict with older data showing a down-regulation 
of miR-223 in resting CD4 T cells from HESN (Bignami F et al, 2012) 
However because our PBMC samples have not been fractionated into 
cellular subset we reasoned that some of the differences in miRNA signature 
could be explained by in/out flux of miRNAs from different cell types.  
The above findings allow the speculation that an initial exposure to sub 
infectious amounts of HIV is sufficient to modify the expression of specific 
miRNA in individuals in whom subsequent exposures to the same virus will 
not result in infection.  Alternatively, it is possible that, higher levels of these 
2 miRNAs are “naturally” present in HESN prior to exposure, and that the 
augmented amounts of these miRNAs are protective or indicative of the 
presence of alternate mechanisms of protection. To further investigate these 
hypotheses we next analyzed miRNAs expression profiles following in vitro 
HIV-1 infection of PBMC from HESN and HC. Unexpectedly, the expression 
of all the analyzed miRNAs was down-regulated to various extents in HESN 
compared to HC after in vitro infection, and differences reached statistically 
significance for miR-28, miR-29a, miR-125b, miR-150 and miR-223. We 
wondered how to reconcile the reduced susceptibility to HIV-1 infection in 
HESN PBMC, as shown by p24 analyses, with the observed decreased 
expression of miRNAs with described anti-HIV properties. Advances in the 
understanding of miRNA physiology, showing that miRNAs can be released 
upon cellular activation, offer a plausible explanation to these results. 
Indeed, recent data indicate that the release of miRNAs in association with 
exosomes, or in association with protein complexes, is not a passive 
phenomenon, but is actually a regulated active process, as shown by the 
fact that exosomal RNA content is not a mere reflection of what is found 
within the intracellular milieu (Zhu W et al, 2009) (Zhang Y et al, 2010). 
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Quantitative analyses hence show a selective enrichment of some miRNAs 
when exosomes are compared to cells. These data suggest that the 
controlled release of miRNAs into exosomes represents an additional layer 
of post-transcriptional regulation for miRNAs that, in this form, can have a 
rapid and effective paracrine effect on target genes of neighboring cells.  
Our working hypothesis indeed is based on the assumption that when the 
immune system is activated upon viral exposure, cells that participate in the 
response will release a detectable quantity of miRNAs into the bloodstream. 
These miRNA will modulate gene expression in paracrine cells, thus 
controlling HIV-1 infection and replication. MicroRNAs release following 
lymphocyte activation is dependent on the magnitude of immune response 
(De Candia P, 2014). Our cohort of HESN is characterized by an immune 
activated phenotype (Mazzoli S et al, 1997) (Biasin M, 2010) it is therefore 
possible to speculate that increased miRNAs release by HESN cells could 
be the logical consequence of a greater responsiveness of their immune 
system to viral exposure. Interestingly, the expression of the miRNAs of 
interest was increased in both cell culture medium of HIV-infected PBMC 
and plasma of HESN. Actually, as Fabbri at al. demonstrated that secreted 
miRNAs, (mainly miR-29a), may act as paracrine agonists of TLRs (Fabbri M 
et al, 2012) and TLR activation has been associated with resistance to HIV-1 
infection (Biasin M, 2010), it is tempting to speculate that these miRNAs 
could be internalized by neighboring cells and modify their susceptibility to 
infection.  
The differences observed in miRNA expression when in vivo and in vitro 
infected PBMCs of HESN were analyzed could be due to the viral load used 
in the experimental procedure. Although the viral burden used in the in vitro 
assay was relatively low, cells were exposed in vitro to concentrations of HIV 
that likely are much higher than those encountered upon natural exposure; 
this could have speed up the release of those miRNA that might have a 
protective effect in controlling HIV infection. An alternate possible 
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explanation is that, whereas PBMC were infected in vitro to an HIV lab strain 
(HIV-1Ba-L), HESN are exposed to primary HIV strains whose virulence is 
likely different.  
In the last step, analyzing miRNA profile in fractionated subpopulations, the 
expression level of miRNA in basal monocyte of HESN clustered with HC 
subjects while HIV+ patients showed lower level of anti HIV-1 miRNA 
expression specifically miR-28, miR-29a, miR-125b and miR-150. 
Interestingly, the expression of miR-198 was exclusively upregulated in 
HESN individuals. It has been demonstrated that although, both monocytes 
and macrophages express anti HIV-1 miRNAs, their level vary from 
monocyte to macrophages, a characteristic that could be correlated with 
their susceptibility to HIV-1 infection (Xu Wang, 2009). Indeed freshly 
isolated monocytes express higher levels of miR-28, miR-150 compared to 
MDM and this increase has been associated with inhibition of HIV-1 
replication (Xu Wang, 2009). Furthermore, Xu Wang et.al found that the 
expression of these miRNA decrease in vitro when monocyte differentiates 
into macrophages.  
In our study, MDM from HESN were less susceptible to HIV-1 infection 9-
days post infection and this reduction was associated with significantly 
increased expression of miR-29a, miR-150, miR-155, miR-190, miR-198 and 
miR-382 compared to HC subjects. These results suggest that the higher 
expression of these miRNAs in both monocyte and MDM of HESN 
individuals could play important roles in resistance to HIV-1 infection in 
HESNs. Also, monocyte and MDM permissivity to HIV infection could be 
affected by the presence of these anti HIV-1 miRNAs. 
Since abnormal miRNA expression seems to characterize many diseases, 
miRNA expression profiles are likely to become important diagnostic and 
prognostic tools as well as potential therapeutic targets. 
The mechanism for miRNAs up regulation in HESN remains elusive. 
Nevertheless if HIV-1 exposure truly affects miRNA transcription and 
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maturation in particular subsets of PBMC, such knowledge might be useful 
for the design of novel HIV-1 therapies and for diagnosis, prognosis and 
treatment response parameters. 
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